# Medical Question & Answer

**Sample ID**: b9f0edce-2b42-b7bd-0e51-8b143c9b80f2
**Dataset Index**: 184579

---

## Question

2006 amlodipine trial

---

## Answer

> Let's see… What do we have here? The user is asking about the "2006 amlodipine trial". Let's break this down step-by-step. First, I need to think about which trial exactly matches that year and involves amlodipine. Then, I should verify the study design, population, interventions, and primary outcomes. Next, I will examine key results and their statistical significance. After that, I need to consider limitations and confounders, especially blood pressure differences. Finally, I will synthesize clinical implications and how this fits with contemporary guidance and other major trials like ALLHAT and VALUE.

> Let me first confirm the trial identity. The most likely match for a "2006 amlodipine trial" is the ACCOMPLISH trial, published in 2008 but with recruitment and follow-up that spanned the mid-2000s and was stopped early for benefit in 2006, which aligns with the user's timeframe. I should double-check that ACCOMPLISH indeed compared an amlodipine-containing regimen and reported superiority, which it did [^ffddeaa1] [^82d532b1].

> Wait, let me verify the design and population. ACCOMPLISH was a randomized, double-blind, multicenter trial in 11,506 high-risk hypertensive patients comparing benazepril plus amlodipine versus benazepril plus hydrochlorothiazide as initial combination therapy, with a mean follow-up of 36 months and early termination for superiority. This is a high-quality, event-driven RCT design, which strengthens inference about cardiovascular outcomes [^ffddeaa1] [^82d532b1].

> I need to check the primary outcome and magnitude of benefit. The primary composite endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitated cardiac arrest, and coronary revascularization occurred in 9.6% with benazepril/amlodipine versus 11.8% with benazepril/HCTZ, yielding a relative risk reduction of 19.6% and an absolute risk reduction of 2.2% (HR 0.80, 95% CI 0.72–0.90; P < 0.001). I should confirm that this benefit persisted across subgroups and was not driven by blood pressure differences, which the trial and subsequent analyses support [^ffddeaa1] [^82d532b1] [^4131d573].

> Hold on, let's not jump to conclusions about mechanism. I initially thought the benefit might be largely due to greater blood pressure lowering with the amlodipine combination, but wait, I should verify that achieved blood pressures were actually similar between groups. Indeed, mean on-treatment BP was about 131.6/73.3 mmHg with benazepril/amlodipine and 132.5/74.4 mmHg with benazepril/HCTZ, so the outcome advantage appears independent of mean BP differences, suggesting class effects and possibly effects on blood pressure variability or vascular biology contribute [^ffddeaa1] [^82d532b1].

> Next, I should review safety and tolerability. Peripheral edema was more frequent with the amlodipine-containing regimen, but discontinuations for adverse events were not higher, and the overall safety profile was acceptable. This aligns with the known dose-related edema risk of amlodipine and supports the clinical trade-off given the outcome benefit [^ffddeaa1] [^82d532b1].

> I will now examine how this fits with the broader evidence base. ALLHAT, the largest antihypertensive RCT, showed no superiority of amlodipine versus chlorthalidone for fatal CHD or nonfatal MI, but amlodipine was associated with more heart failure events, whereas VALUE showed faster early BP control with amlodipine and a lower MI rate versus valsartan, albeit with unequal BP trajectories complicating interpretation. ACCOMPLISH is unique in testing initial combination therapy head-to-head and demonstrating superiority of ACEi/CCB over ACEi/thiazide, which is not directly addressed by ALLHAT or VALUE [^5f5098c7] [^6a102f7c] [^856fd113].

> Let me consider clinical implications carefully. ACCOMPLISH supports choosing an ACE inhibitor plus a calcium channel blocker as initial combination therapy in high-risk hypertensive patients, particularly when dual therapy is indicated, and it reinforces that the choice of combination matters beyond simply lowering blood pressure. Contemporary guidelines endorse several first-line classes, including CCBs, and recognize that many patients require combination therapy to reach targets, making ACCOMPLISH's regimen a reasonable evidence-based option in appropriate patients [^ffddeaa1] [^5c407639].

> But wait, what if the user meant a different 2006-era amlodipine study? I should double-check alternatives. ASCOT-BPLA, often cited for amlodipine-based benefits, was published in 2005 and showed fewer strokes and other events with amlodipine ± perindopril versus atenolol ± thiazide, while CAMELOT, published in 2004, showed event reduction with amlodipine in normotensive CAD patients. Neither of these fits a 2006 label as precisely as ACCOMPLISH does, though they contribute to the amlodipine evidence base [^ff6d62ef] [^23433dd5].

> In summary, I should confirm the bottom line. The "2006 amlodipine trial" most plausibly refers to ACCOMPLISH, which demonstrated that benazepril plus amlodipine reduced cardiovascular events more than benazepril plus hydrochlorothiazide in high-risk hypertensive patients, with similar achieved blood pressures, establishing a meaningful outcome advantage for the ACEi/CCB combination as initial therapy in this population [^ffddeaa1] [^82d532b1].

---

The 2006 amlodipine trial refers to **ACCOMPLISH** [^ffddeaa1], which showed that benazepril plus amlodipine reduced cardiovascular events more than benazepril plus hydrochlorothiazide in high-risk hypertensive patients (9.6% vs 11.8%; HR 0.80, 95% CI 0.72–0.90; P < 0.001) [^82d532b1]. This benefit persisted across subgroups, including patients with diabetes and chronic kidney disease [^4131d573], and was independent of blood pressure differences. Amlodipine-based therapy also slowed CKD progression (2.0% vs 3.7% doubling of creatinine or dialysis; P < 0.01) [^2519f71d]. The trial established ACE inhibitor plus calcium channel blocker as a preferred initial combination in high-risk hypertension [^4131d573].

---

## Study design and methodology

- **Design**: Randomized, double-blind, multicenter trial.
- **Participants**: 11,506 high-risk hypertensive patients aged ≥ 55 years with systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg, or already on antihypertensive therapy.
- **Interventions**: Benazepril 20 mg plus amlodipine 5 mg vs benazepril 20 mg plus hydrochlorothiazide 12.5 mg; doses titrated to achieve BP < 140/90 mmHg.
- **Primary outcome**: Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, coronary revascularization, or resuscitated cardiac arrest [^ffddeaa1].
- **Follow-up**: Mean 36 months; terminated early for superiority.

---

## Key findings

- **Primary outcome**: Lower with benazepril/amlodipine (9.6%) vs benazepril/HCTZ (11.8%); HR 0.80, 95% CI 0.72–0.90; P < 0.001 [^ffddeaa1].
- **Secondary outcomes**: Reduced cardiovascular death, nonfatal MI, and nonfatal stroke (5.0% vs 6.3%; HR 0.79, 95% CI 0.67–0.92; P = 0.002) [^ffddeaa1].
- **Renal outcomes**: Slower CKD progression with benazepril/amlodipine (2.0% vs 3.7% doubling of creatinine or dialysis; P < 0.01) [^2519f71d].
- **Blood pressure**: Similar mean BP achieved in both groups (~132/74 mmHg), indicating BP-independent benefits [^ffddeaa1].

---

## Clinical implications

- **Combination therapy**: ACE inhibitor plus calcium channel blocker is superior to ACE inhibitor plus thiazide for high-risk hypertension [^ffddeaa1].
- **Guideline influence**: Supported adoption of ACEi/CCB combinations as initial therapy in high-risk patients [^notfound].
- **Renal protection**: Amlodipine-based regimens slow CKD progression, expanding their role in patients with or at risk of CKD [^2519f71d].

---

## Limitations and considerations

- **Generalizability**: Benefits are most compelling in high-risk patients; extrapolation to lower-risk populations is uncertain [^289e1ceb].
- **Adverse effects**: Peripheral edema is more common with amlodipine, though discontinuation rates are low [^ffddeaa1].
- **Mechanism**: The advantage likely reflects pleiotropic effects, including reduced vascular inflammation and improved endothelial function, rather than BP differences alone [^notfound].

---

ACCOMPLISH demonstrated that **benazepril plus amlodipine** reduces cardiovascular events and slows CKD progression more than benazepril plus hydrochlorothiazide in high-risk hypertension, establishing ACEi/CCB as a preferred initial combination in this population [^ffddeaa1] [^2519f71d].

---

## References

### Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [^6a102f7c]. Lancet (2004). Excellent credibility.

Background

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.

Methods

15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4.2 years.

Findings

Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4.0/2.1 mm Hg lower in amlodipine than valsartan group after 1 month; 1.5/1.3 mm Hg after 1 year; p < 0.001 between groups). The primary composite endpoint occurred in 810 patients in the valsartan group (10.6%, 25.5 per 1000 patient-years) and 789 in the amlodipine group (10.4%, 24.7 per 1000 patient-years; hazard ratio 1.04, 95% CI 0.94–1.15, p = 0.49).

Interpretation

The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.

---

### The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics [^029a8142]. Journal of Human Hypertension (2011). Low credibility.

Discussion

CHIEF randomized in excess of 13 000 patients between October 2007 and October 2008, of whom 73% were recruited into the lipid-lowering limb.

If CHIEF runs its full course, it should report at the end of 2011. CHIEF will help to define the place of the two different treatment strategies for the lowering of BP, both alone and in combination with lipid-lowering therapy and lifestyle intervention, in the prevention of cardiovascular outcomes.

The recent guidelines on hypertension, and on cardiovascular preventionemphasized that rather than focus on single-risk factors, focus should be on the global cardiovascular risk of an individual patient. The CHIEF study was designed to manage the hypertensive patients on the basis of an extensive intervention of the overall risk, including an initial low dose of combined antihypertensive therapy, low-dose statin-based lipid-lowering treatment and lifestyle intervention. Extensive intervention of overall risks has great potential to control hypertension and other cardiovascular risk factors, to enable more patients to reach their target BP, and further reduce the risk of cardiovascular events.

---

### Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [^4974bd8b]. Circulation (2011). Low credibility.

Background

In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, practice-based, active-control, comparative effectiveness trial in high-risk hypertensive participants, risk of new-onset heart failure (HF) was higher in the amlodipine (2.5–10 mg/d) and lisinopril (10–40 mg/d) arms compared with the chlorthalidone (12.5–25 mg/d) arm. Similar to other studies, mortality rates following new-onset HF were very high (≥ 50% at 5 years), and were similar across randomized treatment arms. After the randomized phase of the trial ended in 2002, outcomes were determined from administrative databases.

Methods and Results

With the use of national databases, posttrial follow-up mortality through 2006 was obtained on participants who developed new-onset HF during the randomized (in-trial) phase of ALLHAT. Mean follow-up for the entire period was 8.9 years. Of 1761 participants with incident HF in-trial, 1348 died. Post-HF all-cause mortality was similar across treatment groups, with adjusted hazard ratios (95% confidence intervals) of 0.95 (0.81–1.12) and 1.05 (0.89–1.25), respectively, for amlodipine and lisinopril compared with chlorthalidone, and 10-year adjusted rates of 86%, 87%, and 83%, respectively. All-cause mortality rates were also similar among those with reduced ejection fractions (84%) and preserved ejection fractions (81%), with no significant differences by randomized treatment arm.

Conclusions

Once HF develops, risk of death is high and consistent across randomized treatment groups. Measures to prevent the development of HF, especially blood pressure control, must be a priority if mortality associated with the development of HF is to be addressed. Clinical Trial Registration- http://www.clinicaltrials.gov. Unique identifier: NCT00000542.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^0d5de8bb]. Open Heart (2016). Low credibility.

The VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial was another large trial enrolling over 15 000 patients with HTN who were previously treated with anti-HTN therapy. This study looked at the efficacy of amlodipine versus valsartan in attaining a BP goal of < 140/90. The doses were uptitrated to 10 mg of amlodipine or 160 mg of valsartan. Two additional steps were done that included adding hydrochlorothiazide (HCTZ) then another agent (excluding ACEIs, ARBs or other CCBs). The outcomes showed that both monotherapy groups had similar improvements in BP with average BPs in the 130s/80s for both groups. However, valsartan caused a significant increase (19%, p = 0.02) in total MI (fatal and nonfatal) in comparison with amlodipine. Although some have criticised these results due to the faster BP lowering of amlodipine early on, the Kaplan-Meier MI curves indicated that as BP became similar between the two groups (as the trial progressed), the curves continued to diverge; suggesting a BP-independent beneficial effect on MI with amlodipine versus valsartan. New-onset diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine.

---

### Mortality and morbidity among individuals with hypertension receiving a diuretic, ACE inhibitor, or calcium channel blocker: a secondary analysis of a randomized clinical trial [^5148c7fe]. JAMA Network Open (2023). High credibility.

Methods

This prespecified secondary analysis of the ALLHAT, a multicenter, randomized, double-blind, active-controlled clinical trial, followed up with participants for up to 23 years, from February 23, 1994, to December 31, 2017. The methods and primary results of the ALLHAT and posttrial outcome results through 2006 have previously been published. Posttrial follow-up data were gathered from the National Death Index (NDI), Social Security Administration, and Center for Medicare & Medicaid Services (CMS) databases from the earliest available date through 2017. Participants in the trial provided written informed consent before study onset, and each of the 623 participating North American study centers obtained institutional review board approval for the trial. The institutional review board of The University of Texas Health Science Center at Houston likewise approved the long-term follow-up study (extension protocol and trial protocol in Supplement 1). This study followed the Consolidated Standards of Reporting Trials reporting guideline.

ALLHAT Participants and Double-Blind Protocol

Participants aged 55 years or older who received a diagnosis of hypertension and had a documented history of CVD, atherosclerotic CVD (ASCVD), and/or another risk factor for CHD were eligible for the ALLHAT. Participants were randomized to 4 treatment groups using a 1.7:1 ratio: chlorthalidone (n = 15 255), lisinopril (n = 9054), amlodipine (n = 9048), or doxazosin (n = 9061). At the beginning of the trial, participants engaged in a titration protocol of their randomized (step 1) medication group aimed at achieving a target blood pressure under 140/90 mm Hg. Participants were offered open-label step 2 and step 3 medications if their blood pressure could not be controlled at the maximum allowed daily dose of the step 1 drug. After completion of the initial titration phase, routine participant visits were scheduled for once every 3 months through the first year of the trial and once every 4 months from that point forward. Because of the limited in-trial follow-up due to early stopping, the doxazosin group was excluded from this extended posttrial follow-up (9061 participants excluded).

Extended Follow-Up Outcome Definitions

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^d28f7fcf]. Open Heart (2016). Low credibility.

The ALLHAT (Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial) was one of the largest BP trials performed to date, which enrolled over 33 000 patients with HTN and one CHD risk factor. The objective of this landmark trial was to determine whether the incidence of CHD or other CV diseases would be lower in those patients treated with a CCB, an ACEI, or a diuretic. Patients were randomised to chlorthalidone, amlodipine, or lisinopril with a mean follow-up of about 4.9 years. Primary outcomes included fatal CHD or non-fatal MI and secondary outcomes included all-cause mortality. There was no significant difference among the groups for the reduction in the primary or secondary outcome of all-cause mortality. It was determined that thiazide diuretics are superior in preventing one or more forms of CV disease and also since they are less expensive should be a first-line agent in the treatment of HTN. However, other commentaries suggested that this finding may be attributed to the fact that thiazides are better at treating volume-dependent HTN, such as the elderly and African-Americans who comprised a large portion of the patient demographics for this study. Although this may be the case, this very large study showed that amlodipine was neither superior nor inferior to thiazide diuretics or ACEIs in managing HTN in patients with other comorbid conditions.

---

### Mortality and morbidity among individuals with hypertension receiving a diuretic, ACE inhibitor, or calcium channel blocker: a secondary analysis of a randomized clinical trial [^19d70ad7]. JAMA Network Open (2023). High credibility.

Limitations

This analysis has some important limitations similar to the last follow-up report. First, participants may have stopped the randomization drug once they were unblinded. The unblinding also may have lead to biases. Second, we were not able to conduct a passive outcome ascertainment for all ALLHAT participants due to data availability (Canadian participants were omitted from mortality and combined mortality and morbidity analyses, and VA participants and those without a Medicare number were omitted from the combined mortality or morbidity analyses), resulting in a reduced sample size. Therefore, the individuals in the morbidity and mortality cohorts may not be representative of the general population. However, there were no noted significant differences in the measured baseline demographic distribution for this cohort compared with the full study. Third, posttrial antihypertensive medication use is unknown between study completion (2002) and 2006, and crossover or regression to more similar medications is possible, which could dilute the original treatment distinctions among the 3 randomization groups. A previous study examined posttrial antihypertensive medications based on Medicare Part D–linked data from 2007 and found significant mixing of antihypertensive classes. For example, in 2007, 44%, 40%, and 41% of those in the chlorthalidone, lisinopril, and amlodipine groups, respectively, were prescribed a thiazide or a thiazide-type diuretic. Fourth, blood pressure and laboratory data were not obtained after the trial. Fifth, after adjustment for multiple comparisons, none of the analyses were statistically significant. We, therefore, interpreted the magnitude of the HRs for consistency with in-trial analysis and previous posttrial analysis with particular caution. However, with 11 years of additional passive follow-up (2006–2017), the results for lisinopril vs chlorthalidone for stroke and stroke mortality are almost the same.

---

### Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [^5f08e840]. JAMA (2002). Excellent credibility.

The study ALLHAT (calcium channel blocker) was published by ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. and colleagues in 2002 in the journal JAMA. This study is related to the following diseases: Hypertension and Coronary artery disease. In the ALLHAT (calcium channel blocker) study, the trial question was: is amlodipine superior to chlorthalidone in high-risk patients with hypertension? In the ALLHAT (calcium channel blocker) study, the study design was: multi-center, double blinded, RCT. In the ALLHAT (calcium channel blocker) study, the population was: 24303 patients (11451 female, 12852 male). The inclusion criteria were patients ≥ 55 years of age with hypertension and at least 1 other coronary artery disease risk factor. The key exclusion criteria were history of hospitalized or treated symptomatic HF and/or known LVEF < 35%. In the ALLHAT (calcium channel blocker) study, the interventions were: n = 9048 amlodipine (a dose of 2.5–10 mg/day) n = 15255 chlorthalidone (a dose of 12.5–25 mg/day). In the ALLHAT (calcium channel blocker) study, the primary outcome was: no significant difference in the rate of fatal coronary artery disease or nonfatal myocardial infarction within 6 years (11.3% vs. 11.5%; RR 0.98, 95% CI 0.9 to 1.07). In the ALLHAT (calcium channel blocker) study, the secondary outcomes were: no significant difference in the rate of death from all causes within 6 years (16.8% vs. 17.3%; RR 0.96, 96% CI 0.89 to 1.02) No significant difference in the rate of coronary artery disease within 6 years (19.9% vs. 19.9%; RR 1, 95% CI 0.94 to 1.07) No significant difference in the rate of stroke within 6 years (5.4% vs. 5.6%; RR 0.93, 95% CI 0.82 to 1.06). In the ALLHAT (calcium channel blocker) study, the safety outcomes were: no significant difference in hospitalization for gastrointestinal bleeding. In the ALLHAT (calcium channel blocker) study, the conclusion was: in patients ≥ 55 years of age with hypertension and at least 1 other coronary artery disease risk factor, amlodipine was not superior to chlorthalidone with respect to the rate of fatal coronary artery disease or nonfatal myocardial infarction within 6 years.

---

### Amlodipine besylate [^502c8dee]. FDA (2025). Medium credibility.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine was well-tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (N = 1730) at doses up to 10 mg to placebo (N = 1250), discontinuation of amlodipine because of adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most commonly reported side effects more frequent than placebo are reflected in the table below. The incidence (%) of side effects that occurred in a dose related manner are as follows:

Other adverse reactions that were not clearly dose related but were reported with an incidence greater than 1.0% in placebo-controlled clinical trials include the following:

For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table:

---

### Design and rationale of the clinical outcomes utilizing revascularization and aggressive druG evaluation (COURAGE) trial veterans affairs cooperative studies program no. 424 [^1858c0d8]. American Heart Journal (2006). Low credibility.

Background

Major improvements in medical therapy and percutaneous coronary intervention (PCI) for coronary heart disease have occurred during the past decade, but no randomized trial has compared these 2 strategies for the "hard" clinical end points of death or myocardial infarction nor have earlier studies incorporated the use of coronary stents and aggressive multifaceted medical therapy during long-term follow-up.

Methods

The COURAGE trial is a multicenter study of patients with documented myocardial ischemia and angiographically confirmed single or multivessel coronary artery disease who are randomized to a strategy of PCI plus intensive medical therapy or intensive medical therapy alone. Medical therapy in both groups is guideline-driven and includes: aspirin, clopidogrel, simvastatin (low-density lipoprotein cholesterol target 60–85 mg/dL), long-acting metoprolol and/or amlodipine, lisinopril or losartan, and long-acting nitrates, as well as lifestyle interventions. The primary end point is a composite of all-cause mortality or acute myocardial infarction, and there will be 85% power to detect an absolute 4.6% (relative 22%) difference between strategies. The principal hypothesis is that PCI plus aggressive medical therapy (projected event rate 16.4%) will be superior to aggressive medical therapy alone (projected event rate 21%) during a 2.5- to 7-year (median of 5 years) follow-up.

Conclusions

COURAGE is the largest prospective randomized trial of PCI versus intensive medical therapy to date and will define the incremental benefits of PCI in the setting of contemporary optimal medical therapy for chronic coronary heart disease. A total of 2287 patients have been enrolled, and follow-up will conclude in June 2006.

---

### Amlodipine besylate (amlodipine) [^d94f64fb]. FDA (2013). Low credibility.

Effects in Vasospastic Angina

In a double-blind, placebo-controlled clinical trial of 4 weeks duration in 50 patients, amlodipine therapy decreased attacks by approximately 4/week compared with a placebo decrease of approximately 1/week (p < 0.01). Two of 23 amlodipine and 7 of 27 placebo patients discontinued from the study due to lack of clinical improvement.

Effects in Documented Coronary Artery Disease

In PREVENT, 825 patients with angiographically documented coronary artery disease were randomized to amlodipine besylate tablets (5–10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction < 40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine besylate tablets (5–10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine besylate tablet and placebo groups respectively for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 1). Effects in various subgroups are shown in Figure 2.

---

### Amlodipine [^7c370462]. FDA (2022). Medium credibility.

14.4 Effects in Documented Coronary Artery Disease

In PREVENT, 825 patients with angiographically documented coronary artery disease were randomized to amlodipine (5 to 10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction < 40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine (5 to 10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540 to 0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 1). Effects in various subgroups are shown in Figure 2.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^02e0641a]. European Heart Journal (2024). Medium credibility.

In the current study, we had the advantage of recall of subgroups of participants during the long-term follow-up. Information derived from these visits demonstrated that, in addition to the fact that BP levels were similar, there was a much greater overlap of drug treatment between the two arms of the trial than reported during the trial. More subjects received amlodipine and angiotensin-converting enzyme inhibitors in those formerly assigned atenolol-based treatment, and the latter were more likely to receive either amlodipine or angiotensin-converting enzyme inhibitors. Thus, whatever the explanation for the benefits of amlodipine-based treatment reported in the original trial, such factors could have persisted, although potentially diluted, during the long-term follow-up.

We have no measure of BPV during follow-up, but if treatment favoured amlodipine-based treatment in those formerly assigned amlodipine, then this could account, at least in part, for the beneficial effects reported in this article. Importantly, few antihypertensive classes of drugs have a substantial effect on visit-to-visit BPV, which seems to be largely accounted for by alterations in compliance and structure in large arteries. In comparisons between drugs, long-acting calcium channel blockers, such as amlodipine and, to a lesser extent non-loop diuretics, reduce long-term visit-to-visit BPV compared with other classes of drugs.

Given the observations that a substantial number of events occur in subjects with normal or controlled BP but high BPV, an important question is to what extent might long-acting calcium channel blockers such as amlodipine reduce the risk of CV events in this group of patients. In the original ASCOT trial, an amlodipine-based treatment regimen reduced the incidence of stroke events by 22% and coronary events by 15% compared with atenolol-based treatment. Subsequent post hoc analyses showed that this was best explained by the reduction of ∼15% in visit-to-visit systolic BPV. This reduction in CV events was independent of mean SBP. This therefore provides an estimate of the potential benefits of amlodipine-based treatment in subjects with well-controlled SBP but high BPV, however, a definitive answer to this question requires a prospectively designed randomized controlled clinical trial.

---

### Valsartan amlodipine randomized trial (VART): design, methods, and preliminary results [^ed383d7c]. Hypertension Research (2008). Low credibility.

Antihypertensive therapy has been well established to reduce hypertension related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, ¹²³I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n = 399) and an amlodipine (n = 398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial.

---

### Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT [^f88a0b3e]. Journal of General Internal Medicine (2014). Low credibility.

Background

Hypertension is a major risk factor for peripheral artery disease (PAD). Little is known about relative efficacy of antihypertensive treatments for preventing PAD.

Objectives

To compare, by randomized treatment groups, hospitalized or revascularized PAD rates and subsequent morbidity and mortality among participants in the Antihypertensive and Lipid-Lower Treatment to Prevent Heart Attack Trial (ALLHAT).

Design

Randomized, double-blind, active-control trial in high-risk hypertensive participants.

Participants

Eight hundred thirty participants with specified secondary outcome of lower extremity PAD events during the randomized phase of ALLHAT.

Interventions/Events

In-trial PAD events were reported during ALLHAT (1994–2002). Post-trial mortality data through 2006 were obtained from administrative databases. Mean follow-up was 8.8 years.

Main Measures

Baseline characteristics and intermediate outcomes in three treatment groups, using the Kaplan-Meier method to calculate cumulative event rates and post-PAD mortality rates, Cox proportional hazards regression model for hazard ratios and 95% confidence intervals, and multivariate Cox regression models to examine risk differences among treatment groups.

Key Results

Following adjustment for baseline characteristics, neither participants assigned to the calcium-channel antagonist amlodipine nor to the ACE-inhibitor lisinopril showed a difference in risk of clinically advanced PAD compared with those in the chlorthalidone arm (HR, 0.86; 95% CI, 0.72–1.03 and HR, 0.98; 95% CI, 0.83–1.17, respectively). Of the 830 participants with in-trial PAD events, 63% died compared to 34% of those without PAD; there were no significant treatment group differences for subsequent nonfatal myocardial infarction, coronary revascularizations, strokes, heart failure, or mortality.

Conclusions

Neither amlodipine nor lisinopril showed superiority over chlorthalidone in reducing clinically advanced PAD risk. These findings reinforce the compelling need for comparative outcome trials examining treatment of PAD in high-risk hypertensive patients. Once PAD develops, cardiovascular event and mortality risk is high, regardless of type of antihypertensive treatment.

---

### Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial [^098f46d3]. Lancet (2011). Excellent credibility.

Background

Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control by monotherapy impairs subsequent control by combination therapy.

Methods

We did a double-blind, randomised, parallel-group, superiority trial at 146 primary and secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009. Patients eligible for enrolment had essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mmHg. Patients were randomly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine. Random assignment was through a central interactive voice response system and treatment allocation was masked from the patients. From 16–32 weeks, all patients received combination therapy with 300 mg aliskiren plus 10 mg amlodipine. Our primary endpoints, assessed on an intention-to-treat basis (ie, in patients who received the allocated treatment), were the adjusted mean reduction in systolic blood pressure from baseline over 8 to 24 weeks, and then the final reduction at 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862.

Findings

318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine. 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis. Patients given initial combination therapy had a 6.5 mmHg (95% CI 5.3 to 7.7) greater reduction in mean systolic blood pressure than the monotherapy groups (p < 0.0001). At 24 weeks, when all patients were on combination treatment, the difference was 1.4 mmHg (95% CI -0.05 to 2.9; p = 0.059). Adverse events caused withdrawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group. Adverse events were peripheral oedema, hypotension, or orthostatic hypotension.

Interpretation

We believe that routine initial reduction in blood pressure (> 150 mmHg) with a combination such as aliskiren plus amlodipine can be recommended.

Funding

Novartis Pharma AG.

---

### Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension [^9378b79f]. Clinical Therapeutics (2007). Low credibility.

Background

Patients with hypertension may require combination therapy to attain the blood pressure targets recommended by US and European treatment guidelines. Combination therapy with a calcium channel blocker and an angiotensin II-receptor blocker would be expected to provide enhanced efficacy.

Objectives

Two studies were conducted to compare the efficacy of various combinations of amlodipine and valsartan administered once daily with their individual components and placebo in patients with mild to moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] ≥ 95 and < 110 mm Hg). A secondary objective was to evaluate safety and tolerability.

Methods

The 2 studies were multinational, multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group trials. In study 1, patients were randomized to receive amlodipine 2.5 or 5 mg once daily, valsartan 40 to 320 mg once daily, the combination of amlodipine 2.5 or 5 mg with valsartan 40 to 320 mg once daily, or placebo. In study 2, patients were randomized to receive amlodipine 10 mg once daily, valsartan 160 or 320 mg once daily, the combination of amlodipine 10 mg with valsartan 160 or 320 mg once daily, or placebo. The primary efficacy variable in both studies was change from baseline in MSDBP at the end of the study. Secondary variables included the change in mean sitting systolic blood pressure (MSSBP), response rate (the proportion of patients achieving an MSDBP < 90 mm Hg or a ≥ 10-mm Hg decrease from baseline), and control rate (the proportion of patients achieving an MSDBP < 90 mm Hg). Safety was assessed in terms of adverse events (spontaneously reported or elicited by questioning), vital signs, and laboratory values.

Results

A total of 1911 patients were randomized to treatment in study 1 (1022 amlodipine + valsartan; 507 valsartan; 254 amlodipine; 128 placebo); 1250 were randomized to treatment in study 2 (419, 415, 207, and 209, respectively). In all treatment groups in both studies, the majority of patients were white (79.5% study 1, 79.4% study 2) and male (53.5% and 50.3%, respectively). The overall mean age was 54.4 years in study 1 and 56.9 years in study 2. The mean weight of patients in study 1 was higher than that in study 2 (88.8 vs 79.7 kg). The overall baseline mean sitting BP was 152.8/99.3 mm Hg in study 1 and 156.7/99.1 mm Hg in study 2. With the exception of a few combinations that included amlodipine 2.5 mg, the combination regimens in both studies were associated with significantly greater reductions in MSDBP and MSSBP compared with their individual components and placebo (P < 0.05). A positive dose response was observed for all combinations. The highest response rate in study 1 was associated with the highest dose of combination therapy (amlodipine 5 mg + valsartan 320 mg: 91.3%). Amlodipine 5 mg, valsartan 320 mg, and placebo were associated with response rates of 71.9%, 73.4%, and 40.9%, respectively. In study 2, the 2 doses of combination therapy were associated with similar response rates (amlodipine 10 mg + valsartan 160 mg: 88.5%; amlodipine 10 mg + valsartan 320 mg: 87.5%). Amlodipine 10 mg was associated with a response rate of 86.9%; valsartan 160 and 20 mg were associated with response rates of 74.9% and 72.0%, respectively; and placebo was associated with a response rate of 49.3%. Control rates followed a similar pattern. The incidence of peripheral edema with combination therapy was significantly lower compared with amlodipine monotherapy (5.4% vs 8.7%, respectively; P = 0.014), was significantly higher compared with valsartan monotherapy (2.1%; P < 0.001), and did not differ significantly from placebo (3.0%).

Conclusions

In these adult patients with mild to moderate hypertension, the combination of amlodipine + valsartan was associated with significantly greater blood pressure reductions from baseline compared with amlodipine or valsartan monotherapy or placebo. The incidence of peripheral edema was significantly lower with combination therapy than with amlodipine monotherapy.

---

### ALLHAT, or the soft science of the secondary end point [^34b593d2]. Annals of Internal Medicine (2003). Low credibility.

The recent Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that the primary end point, coronary heart disease, was identical in the chlorthalidone, lisinopril, and amlodipine groups. Yet the major conclusion of this trial was that thiazide diuretics are superior in preventing 1 or more major forms of cardiovascular disease and should be preferred for first-line antihypertensive therapy. This conclusion was based solely on an analysis of secondary end points and cost. As evidenced by the dictum to "use thiazides for most patients with uncomplicated hypertension" in the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, this interpretation of ALLHAT broadly adumbrated these guidelines. Although diuretics will rightfully remain a cornerstone in antihypertensive therapy, we should remember (as we were told by the ALLHAT investigators) that secondary end points are "soft data" that should not form a basis for main conclusions or lead to a labeling of a drug class as preferred.

---

### Amlodipine besylate (amlodipine) [^303f2dc7]. FDA (2013). Low credibility.

In a angiographic substudy (n = 274) conducted within CAMELOT, there was no significant difference between amlodipine and placebo on the change of atheroma volume in the coronary artery as assessed by intravascular ultrasound.

Figure 1: Kaplan-Meier analysis of composite clinical outcomes for amlodipine versus placebo

>

Figure 2 – Effects on primary endpoint of amlodipine versus placebo across sub-groups

Table 1 below summarizes the significant clinical outcomes from the composites of the primary endpoint. The other components of the primary endpoint including cardiovascular death, resuscitated cardiac arrest, myocardial infarction, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease did not demonstrate a significant difference between amlodipine and placebo.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^2602ee87]. European Heart Journal (2024). Medium credibility.

In sensitivity analyses, analysing time to these outcomes restricted to the post-trial follow-up period in the 7092 participants who were alive at the end of the trial and, who had at least 3 visits at which BP measurements were recorded, we found consistent results with the main analyses. Those on amlodipine-based (vs. atenolol-based) treatment had a significantly reduced risk of stroke [HR 0.84 (95% CI 0.73–0.98), P = 0.028], total CV events and procedures [HR 0.93 (95% CI 0.87–0.99), P = 0.022], total coronary events [HR 0.93 (95% CI 0.86–1.01), P = 0.078], and atrial fibrillation [HR 0.89 (95% CI 0.81–0.98), P = 0.015].

The subgroups of participants who were recalled during the follow-up period — a median of 6 years after the end of the trial — were broadly representative of the total ASCOT Legacy population (see Supplementary data online, Table S2). Blood pressure levels were similar 6 years post-trial closure amongst those formerly assigned amlodipine-compared with atenolol-based treatment (140.6/75.1 and 139.9/75.9 mmHg, respectively; Supplementary data online, Table S3). Supplementary data online, Table S4 provides details of antihypertensive drug use in the participants formerly assigned to the two treatment groups. There was extensive treatment cross over between participants previously assigned amlodipine-based treatment to beta-blockers and/or diuretics. Likewise, in those formerly assigned atenolol-based treatment, many were now receiving calcium channel blockers and/or angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

---

### Amlodipine besylate and atorvastatin calcium [^d0228b6f]. FDA (2021). Medium credibility.

14.4 Amlodipine for Coronary Artery Disease

In PREVENT, 825 patients with angiographically documented CAD were randomized to amlodipine (5 to 10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction < 40%. Patients (76% males, 89% Caucasian, 93% enrolled at U.S. sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine (5 to 10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anticoagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 8). Effects in various subgroups are shown in Figure 2.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^6c412dbd]. Open Heart (2016). Low credibility.

Conclusion

Amlodipine is an excellent first-line choice among the myriad options of antihypertensive agents. In the studies discussed in this manuscript, amlodipine was highly effective for the treatment of HTN and stable angina as evidenced by the fewer hospitalisations for unstable angina and revascularisation in randomised controlled trials. Amlodipine has also shown robust reductions on CV end points (especially stroke) but has not altered the prognosis in HF. Its abilities to prevent activation of counter-regulatory mechanisms, to slow the progression of atherosclerosis, to confer antioxidant properties and to enhance NO production are all unique actions. The management of HTN is shifting more towards dual or even triple combination therapy and requires a patient profiling approach as the number of comorbid states increases. Amlodipine is a superior option in the HTN armamentarium, not only for controlling BP but also for safely improving patient outcomes.

---

### A new dimension in hypertension management with the amlodipine / perindopril combination [^b0447cf4]. Journal of Hypertension (2011). Low credibility.

Recent guidelines are consistent in acknowledging that most hypertensive patients need at least two drugs for optimal blood pressure (BP) control. Trial data are available to support the use of a renin-angiotensin system (RAS) blocker (ie, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker), plus a diuretic, a RAS blocker plus a calcium channel blocker (CCB), and a CCB plus a diuretic. The ACCOMPLISH trial demonstrated somewhat convincingly that an ACE inhibitor/CCB is superior to the same ACE inhibitor plus a thiazide. In the ASCOT trial, amlodipine/perindopril was superior to beta-blocker/thiazide in its effects on all major cardiovascular outcomes and new-onset diabetes. Further substudies of ASCOT provided plausible explanations for the benefits of amlodipine/perindopril strategy. In the CAFE substudy, amlodipine/perindopril was significantly more effective in the reduction of central BP as compared to atenolol/bendroflumethiazide, despite similar brachial BP reduction. More recently, analysis of long-term BP variability provided a further explanation for the reduction of cardiovascular events with amlodipine/perindopril in ASCOT. Thus, the combination of perindopril and amlodipine seems an ideal logical evidence-based pair of antihypertensive agents to select.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^e8e42819]. Open Heart (2016). Low credibility.

Figure 1
ACCOMPLISH: the amlodipine+benazepril combination lowered the primary end point by a relative risk reduction was 20% (HR 0.80; 95% CI 0.72 to 0.90; p < 0.001).

The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) included a total of 19 257 patients with HTN (baseline BP, 164/95 mm Hg) and at least three other cardiac risk factors. This trial, which was stopped for benefit after 5.5 years, showed that the amlodipine+perindopril versus atenolol+thiazide diuretic significantly reduced all-cause mortality (RRR, 11%; p = 0.0247; figure 2). Additionally, amlodipine+perindopril reduced CV mortality by 24% (p = 0.001), coronary events by 13% (p = 0.007) and strokes by 23% (p = 0.0003). At the point where rates of CV death diverged (red arrow) most of the patients (78%) were treated with the combination of perindopril+amlodipine rather than amlodipine monotherapy.

Figure 2
ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide therapy. ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CV, cardiovascular; RRR, relative risk reduction.

The Assessment of combination Therapy of Amlodipine/Ramipril (ATAR) study was an 18-week randomised prospective double-blinded Brazilian study which compared the combination of amlodipine and ramipril versus amlodipine monotherapy. The mean changes in ambulatory BP measurements were statistically significant between the combination versus the amlodipine monotherapy group, 18.7% vs 7.6%, p = 0.011, respectively. In addition, the reported incidence of peripheral oedema was lower in the combination group.

---

### Amlodipine and valsartan [^4c559161]. FDA (2025). Medium credibility.

14 CLINICAL STUDIES

Amlodipine and valsartan was studied in 2 placebo-controlled and 4 active-controlled trials in hypertensive patients. In a double-blind, placebo-controlled study, a total of 1012 patients with mild-to-moderate hypertension received treatments of 3 combinations of amlodipine and valsartan (5/80, 5/160, 5/320 mg) or amlodipine alone (5 mg), valsartan alone (80, 160, or 320 mg) or placebo. All doses with the exception of the 5/320 mg dose were initiated at the randomized dose. The high dose was titrated to that dose after a week at a dose of 5/160 mg. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.

In a double-blind, placebo-controlled study, a total of 1246 patients with mild to moderate hypertension received treatments of 2 combinations of amlodipine and valsartan (10/160, 10/320 mg), or amlodipine alone (10 mg), valsartan alone (160 or 320 mg) or placebo. With the exception of the 10/320 mg dose, treatment was initiated at the randomized dose. The high dose was initiated at a dose of 5/160 mg and titrated to the randomized dose after 1 week. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^1b7bcb70]. European Heart Journal (2024). Medium credibility.

Conclusions

Contemporary clinical practice, based on current guidelines, dictates that treatment decisions in hypertensive patients are determined by levels of SBP and diastolic BP. Our studies, however, provide robust evidence that visit-to-visit BPV is a far more powerful determinant of CV outcome and that at least half of all CV events in our cohort occurred in those with controlled BP but high BPV. We suggest that cut-off of SD for systolic BPV of 13 or more amongst those with 'controlled BPs for a period of time' may in itself suggest a need to act on the excess risk, although we acknowledge, this needs to be supported by further research to establish BPV as a new paradigm for the determinant of thresholds and targets for intervention.

This study also confirms the long-term benefits of amlodipine-based treatment in reducing the risk of stroke, coronary events, and all CV events. The significant reduction in incident stroke beyond the end of the trial may be mediated in part by the reduced incidence of atrial fibrillation and lower SBP variability associated with amlodipine-based treatment.

Long-term benefits of particular treatment strategies have profound clinical implications. The original results of ASCOT-BPLA influenced national and international guidelines for hypertension. The current observations extend the benefits reported in the trial for the amlodipine-based treatment regimen and highlight the increasing importance of visit-to-visit systolic BPV in the prediction of long-term CV outcomes.

---

### Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [^5f5098c7]. JAMA (2002). Excellent credibility.

Context

Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.

Objective

To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.

Design

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.

Setting and Participants

A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.

Interventions

Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years.

Main Outcome Measures

The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).

Results

Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90–1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91–1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P = 0.03) and lisinopril (2 mm Hg, P < .001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P < .001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25–1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05–1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02–1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07–1.31).

Conclusion

Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.

---

### A randomized, placebo-controlled trial of amlodipine in children with hypertension [^4654ec13]. The Journal of Pediatrics (2004). Low credibility.

Objectives

Evaluation of the efficacy and safety of amlodipine in hypertensive children.

Study Design

A randomized, double blinded, placebo-controlled, parallel-group, dose-ranging study was conducted at 49 centers in North and South America. The primary end point was the effect of amlodipine on systolic blood pressure (BP); secondary end points included the effect of amlodipine on diastolic BP, the effect of amlodipine as a function of dose and body size, and evaluation of safety.

Results

We enrolled 268 hypertensive children (mean age, 12.1 ± 3.3 years); 84 (31.3%) had primary hypertension, and 177 (66%) were boys. Amlodipine produced significantly greater reductions in systolic BP than placebo; these were -6.9 mm Hg for 2.5 mg daily (P = 0.045 vs placebo) and -8.7 mm Hg for 5 mg daily (P = 0.005 vs placebo). The underlying cause of hypertension had no effect on the response to amlodipine. There was a significant dose-response effect of amlodipine on both systolic and diastolic BP beginning at doses ≥ 0.06 mg/kg per day. Systolic BP ≤ 95(th) percentile was achieved in 34.6% of subjects with systolic hypertension. Amlodipine was well tolerated, with just 6 children withdrawn from treatment because of drug-related adverse events.

Conclusions

Amlodipine effectively lowers systolic BP in a dose-dependent manner in hypertensive children who require drug treatment.

---

### Impact of amlodipine-based therapy among older and younger patients in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA) [^280db93a]. Journal of Hypertension (2011). Low credibility.

Objectives

Older patients experience higher rates of cardiovascular disease than younger patients, but studies have suggested that relative risk reductions due to antihypertensive therapy are lower in older than younger patients. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) allowed an evaluation of the efficacy and safety of an amlodipine versus an atenolol-based antihypertensive regimen among older (≥ 65 years) and younger (< 65 years) patients.

Methods

In ASCOT-BPLA 19 257 patients (8137 aged ≥ 65 years and 11 020 < 65 years) were randomly assigned to receive amlodipine or atenolol-based antihypertensive therapy. The primary endpoint (nonfatal myocardial infarction and fatal coronary heart disease) and seven secondary endpoints were consistent with the original trial design.

Results

All cardiovascular endpoints evaluated favoured the amlodipine-based regimen, significantly so in seven of the 16 age-stratified endpoints. Compared with the atenolol-based regimen, the amlodipine-based regimen reduced the relative risk of cardiovascular events by 17% in older and 15% in younger patients (P < 0.01). Overall, older patients experienced more cardiovascular events [n = 1625 (20%)] than younger patients [n = 1339 (12%)]. Discontinuations due to serious adverse events were low in both age groups and less frequent in the amlodipine-based versus atenolol-based regimen: 0.6 versus 1.1% among older patients and 0.4 versus 0.8% among younger patients.

Conclusions

The amlodipine-based regimen reduced the relative risk of cardiovascular events more effectively than the atenolol-based regimen in both older and younger patients. However, because event rates were higher among older patients, the absolute benefits were greater for older compared with younger patients.

---

### Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial [^e73884d3]. JAMA Internal Medicine (2017). Medium credibility.

Importance

On the basis of observational studies, the use of thiazide diuretics for the treatment of hypertension is associated with reduced fracture risk compared with nonuse. Data from randomized clinical trials are lacking.

Objective

To examine whether the use of thiazide diuretics for the treatment of hypertension is associated with reduced fracture risk compared with nonuse.

Design, Setting, and Participants

Using Veterans Affairs and Medicare claims data, this study examined hip and pelvic fracture hospitalizations in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial participants randomized to first-step therapy with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), or an angiotensin-converting enzyme inhibitor (lisinopril). Recruitment was from February 1994 to January 1998; in-trial follow-up ended in March 2002. The mean follow-up was 4.9 years. Posttrial follow-up was conducted through the end of 2006, using passive surveillance via national databases. For this secondary analysis, which used an intention-to-treat approach, data were analyzed from February 1, 1994, through December 31, 2006.

Main Outcomes and Measures

Hip and pelvic fracture hospitalizations.

Results

A total of 22 180 participants (mean [SD] age, 70.4 [6.7] years; 43.0% female; and 49.9% white non-Hispanic, 31.2% African American, and 19.1% other ethnic groups) were followed for up to 8 years (mean [SD], 4.9 [1.5] years) during masked therapy. After trial completion, 16 622 participants for whom claims data were available were followed for up to 5 additional years (mean [SD] total follow-up, 7.8 [3.1] years). During the trial, 338 fractures occurred. Participants randomized to receive chlorthalidone vs amlodipine or lisinopril had a lower risk of fracture on adjusted analyses (hazards ratio [HR], 0.79; 95% CI, 0.63–0.98; P = 0.04). Risk of fracture was significantly lower in participants randomized to receive chlorthalidone vs lisinopril (HR, 0.75; 95% CI, 0.58–0.98; P = 0.04) but not significantly different compared with those randomized to receive amlodipine (HR, 0.82; 95% CI, 0.63–1.08; P = 0.17). During the entire trial and posttrial period of follow-up, the cumulative incidence of fractures was nonsignificantly lower in participants randomized to receive chlorthalidone vs lisinopril or amlodipine (HR, 0.87; 95% CI, 0.74–1.03; P = 0.10) and vs each medication separately. In sensitivity analyses, when 1 year after randomization was used as the baseline (to allow for the effects of medications on bone to take effect), similar results were obtained for in-trial and in-trial plus posttrial follow-up.

Conclusions and Relevance

These findings from a large randomized clinical trial provide evidence of a beneficial effect of thiazide-type diuretic therapy in reducing hip and pelvic fracture risk compared with treatment with other antihypertensive medications.

Trial Registration

clinicaltrials.gov Identifier: NCT00000542.

---

### Amlodipine and valsartan [^fc280539]. FDA (2025). Medium credibility.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Studies with Amlodipine and Valsartan:

Amlodipine and valsartan has been evaluated for safety in over 2600 patients with hypertension; over 1440 of these patients were treated for at least 6 months and over 540 of these patients were treated for at least 1 year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.

The hazards [see Warnings and Precautions (5)] of valsartan are generally independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter.

The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In placebo-controlled clinical trials, discontinuation due to side effects occurred in 1.8% of patients in the amlodipine and valsartan‑treated patients and 2.1% in the placebo-treated group. The most common reasons for discontinuation of therapy with amlodipine and valsartan were peripheral edema (0.4%), and vertigo (0.2%).

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^53a9362c]. Open Heart (2016). Low credibility.

One of the pivotal trials assessing amlodipine's role in atherosclerosis was the Prospective Randomized Evaluation of the Vascular Effects of Norvasc (PREVENT) trial. PREVENT assessed the development and progression of atherosclerosis in patients with known CAD. This was a multicentre, randomised, placebo-controlled, double-blinded study, which looked at 825 patients with angiographically documented CAD. Patients were followed over a 3-year period and the primary end point was change in mean diameter over 36 months in segments with a baseline of 30% stenosis. It has been suggested that acute coronary syndrome does not usually result from more stable plaques but rather rupture of minimal lesions. PREVENT also assessed the rate of progression of carotid atherosclerosis which was assessed by CIMT. The data showed that there was no effect on the risk of all-cause mortality or major CV events, and amlodipine did not alter the development of or slow the progression of CAD lesions. However, there was a statistically significant effect on the progression of carotid artery atherosclerosis (p = 0.007). Yet, the study had low statistical power for the detection of a treatment difference in mortality and major morbidity rates because of the relatively low event rates (ie, < 2%/year for MI). When major and other documented vascular events/procedures were combined (increasing the power to determine an effect), there were fewer events in the amlodipine group. Additionally, amlodipine did show reduced rates of unstable angina and coronary revascularisation, which is comparable to data seen with treatment with BB, nitrates and lipid-lowering agents. Angiographic trials with nifedipine or nicardipine did not show these effects. The authors of PREVENT did report that when the event rates for unstable angina and coronary revascularisation were assessed closely, these curves diverged very early (in the first year). Thus, while amlodipine may not have shown a significant role in prevention of progression of early coronary atherosclerotic lesions, it does have a beneficial effect in reducing hospitalisation rates for angina and coronary revascularisation. In the randomised trial Coronary Angioplasty Amlodipine Restenosis Study (CAPARES), patients had a reduced incidence of repeat percutaneous transluminal coronary angioplasty when treated with amlodipine.

The beneficial effects of amlodipine go beyond calcium channel blockade for HTN management. Although many of these trials show that amlodipine is not superior to other agents in preventing CAD, it can be safely used in patients with CAD for the management of HTN.

---

### VALUE trial: long-term blood pressure trends in 13, 449 patients with hypertension and high cardiovascular risk [^1e38b063]. American Journal of Hypertension (2003). Low credibility.

Background

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment.

Methods

The blood pressure (BP) trends are analyzed in 13,449 of VALUE study patients who had baseline BP and 24 months BP and treatment data.

Results

In a cohort of 12,570 patients, baseline 24 and 30 months BP, but not 30 months treatment data, were available. Of 13,449 patients, 92% (N = 12,398) received antihypertensive therapy at baseline. The baseline BP was 153.5/86.9 mm Hg in treated compared to 168.1.8/95.3 mm Hg in 1051 untreated patients. After 6 months both groups had indistinguishable BP values. At 12 months the BP decreased to 141.2/82.9 mm Hg (P < .0001 for systolic BP and diastolic BP versus baseline), at 24 months to 139.1/80 mm Hg (P < .0001 v 12 months), and to 138/79 mm Hg at 30 months (P < .0001 v 24 months). The systolic BP control (< 140 mm Hg) at 30 months increased from 21.9% at baseline to 62.2%, the diastolic BP (< 90 mm Hg) from 54.2% to 90.2% and the combined control (< 140 and < 90 mm Hg) from 18.9% to 60.5%. At 24 months 85.8% of patients were on protocol drugs: monotherapy = 39.7%, added hydrochlorothiazide = 26.6%, add-on drugs = 15.1%, and protocol drugs in nonstandard doses = 4.3%.

Conclusions

The achieved BP control exceeds values reported in most published large-scale trials. The VALUE study is executed in regular clinical settings and 92% of the patients received antihypertensive drugs at baseline. When an explicit BP goal is set, and a treatment algorithm is provided, the physicians can achieve better control rates than in their regular practice.

---

### Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients [^ffddeaa1]. The New England Journal of Medicine (2008). Excellent credibility.

The study ACCOMPLISH was published by Jamerson K and colleagues in 2008 in the journal N Engl J Med. This study is related to the following diseases: Hypertension. In the ACCOMPLISH study, the trial question was: is benazepril plus amlodipine superior to benazepril plus hydrochlorothiazide in patients with hypertension who are at high-risk for cardiovascular events? In the ACCOMPLISH study, the study design was: multi-center, double blinded, RCT. In the ACCOMPLISH study, the population was: 11506 patients (4543 female, 6963 male). The inclusion criteria were patients with hypertension who were at high risk for cardiovascular events. The key exclusion criteria were acute coronary syndromes, or coronary revascularizations within 1 month of the first visit; stroke or other ischemic cerebrovascular episodes within 3 months preceding study evaluation; or hypertension that is excessively severe, known to be refractory to treatment, or known to have a secondary cause. In the ACCOMPLISH study, the interventions were: n = 5744 benazepril-amlodipine (20 mg benazepril and 5 mg amlodipine) n = 5762 benazepril-hydrochlorothiazide (20 mg benazepril and 12.5 mg hydrochlorothiazide). In the ACCOMPLISH study, the primary outcome was: significant decrease in the rate of cardiovascular events and death from cardiovascular causes, at a mean follow-up of 36 months (9.6% vs. 11.8%; HR 0.8, 95% CI 0.72 to 0.9). In the ACCOMPLISH study, the secondary outcomes were: significant decrease in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke (5% vs. 6.3%; HR 0.79, 95% CI 0.67 to 0.92) Significant decrease in cardiovascular events (8.6% vs. 10.3%; HR 0.83, 95% CI 0.73 to 0.93). In the ACCOMPLISH study, the safety outcomes were: no significant difference in dry cough (20.5% vs. 21.2%) and hyperkalemia (0.6% vs. 0.6%). significant differences in peripheral edema (31.2% vs. 13.4%), dizziness (20.7% vs. 25.4%), and hypotension (2.5% vs. 3.6%). In the ACCOMPLISH study, the conclusion was: in patients with hypertension who were at high risk for cardiovascular events, benazepril-amlodipine was superior to benazepril-hydrochlorothiazide with respect to the rate of cardiovascular events and death from cardiovascular causes, at a mean follow-up of 36 months.

---

### Results of a multicenter, 8-week, parallel-group, randomized, double-blind, double-dummy, phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension [^e63814ae]. Clinical Therapeutics (2005). Low credibility.

Background

Recently, amlodipine maleate was developed and tested in preclinical and Phase I clinical trials in Korea. The studies found pharmacokinetics and pharmacodynamics similar to those of amlodipine besylate.

Objective

The aim of this study was to compare the efficacy and tolerability of amlodipine maleate with those of amlodipine besylate in Korean patients with mild to moderate hypertension.

Methods

This was a multicenter, 8-week, parallel-group, randomized, double-blind, double-dummy, Phase III clinical trial. Eligible patients were Korean, aged 18 to 75 years, had hypertension, and were either taking antihypertensive medications or had a documented sitting diastolic blood pressure of 90 to 109 mm Hg. After a washout period of 2 weeks, patients were randomized to amlodipine maleate or amlodipine besylate for 8 weeks. In both groups, the medications were initiated at 5 mg QD. At day 29, the medication dose was increased to 10 mg QD if sitting diastolic blood pressure (SiDBP) was ≥ 90 mm Hg.

Results

One hundred eighteen patients were enrolled. Fifty-seven patients received amlodipine maleate (29 men, 28 women; mean [SD] age, 49.0 [11.4] years) and 61 received amlodipine besylate (35 men, 26 women; mean [SD] age, 51.6 [9.4] years). Baseline mean (SD) values for sitting systolic blood pressure and SiDBP were 152.0 (12.2) mm Hg and 98.1 (5.6) mm Hg, respectively, for the amlodipine maleate group and 153.4 (14.0) mm Hg and 98.1 (5.5) mm Hg, respectively, for the amlodipine besylate group. In this population, amlodipine maleate was not inferior to amlodipine besylate: the lower limit of the 2-sided 95% CI for the treatment difference in SiDBP was greater than -4 mm Hg. The between-group difference in SiDBP response rate (the proportion of patients who experienced adequate SiDBP reductions) did not reach statistical significance: 85.7% (42/49) for the amlodipine maleate group and 91.8% (45/49) for the amlodipine besylate group. Compliance rates were similar between groups, with mean (SD) compliance rates of 97.4% (2.8%) and 97.1% (3.6%) in the amlodipine maleate and amlodipine besylate groups, respectively. Also, there were no significant differences in the incidences of drug-related clinical and laboratory adverse events; the most common were headache, flushing, facial edema, and paresthesia.

Conclusion

In this population, the efficacy and tolerability observed with amlodipine maleate were similar to those seen with amlodipine besylate.

---

### Amlodipine besylate and valsartan (Amlodipine and valsartan) [^1fc6b33c]. FDA (2018). Low credibility.

Two additional double-blind, active-controlled studies were conducted in which amlodipine and valsartan tablets were administered as initial therapy. In 1 study, a total of 572 black patients with moderate to severe hypertension were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 12 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by optional titration to 10/320 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by optional titration to 10 mg for 4 weeks and optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 8 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.7/2.8 mmHg.

In the other study of similar design, a total of 646 patients with moderate to severe hypertension (MSSBP of ≥ 160 mmHg and < 200 mmHg) were randomized to receive either combination amlodipine/valsartan or amlodipine monotherapy for 8 weeks. The initial dose of amlodipine/valsartan was 5/160 mg for 2 weeks with forced titration to 10/160 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. The initial dose of amlodipine was 5 mg for 2 weeks with forced titration to 10 mg for 2 weeks, followed by the optional addition of HCTZ 12.5 mg for 4 weeks. At the primary endpoint of 4 weeks, the treatment difference between amlodipine/valsartan and amlodipine was 6.6/3.9 mmHg.

There are no trials of amlodipine and valsartan combination tablets demonstrating reductions in cardiovascular risk in patients with hypertension, but the amlodipine component and several ARBs, which are the same pharmacological class as the valsartan component, have demonstrated such benefits.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^a32f44aa]. Open Heart (2016). Low credibility.

Role as monotherapy in HTN

Several HTN trials have investigated the efficacy of amlodipine monotherapy versus other agents, including diuretics, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). The outcomes of these trials suggest that amlodipine has a neutral effect on several pre-existing comorbid states, which will be discussed below.

The Comparison of Amlodipine versus Enalapril to Limit Occurrence of Thrombosis (CAMELOT) trial, enrolled 1991 patients with angiographically documented coronary artery disease (CAD) and randomised them to amlodipine 10 mg, enalapril 20 mg, or placebo and followed them over 24 months. Atherosclerotic progression was also assessed in a substudy of 274 patients as well using intravascular ultrasound. Although the baseline BP was low to begin with, 129/78, both groups showed similar BP lowering, 4.8/2.5 and 4.9/2.4 for amlodipine and enalapril, respectively. Amlodipine significantly reduced non-fatal myocardial infarction (MI) by 26% and stroke or transient ischaemic attack by 50% (number needed to treat = 16), whereas enalapril had no significant benefit compared with placebo. Moreover, there was a statistically significant reduction in hospitalisation rate for angina (p = 0.003) with amlodipine versus enalapril. This study suggests that normotensive patients treated with amlodipine show reduced rates of CV events and hospitalisations compared with enalapril and evidence of slowing of atherosclerotic progression.

---

### Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial [^de814cd3]. JAMA (2001). Excellent credibility.

Context

Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans.

Objective

To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (metoprolol) on hypertensive renal disease progression.

Design, Setting, and Participants

Interim analysis of a randomized, double-blind, 3 × 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20–65 mL/min per 1.73 m²) enrolled between February 1995 and September 1998. This report compares the ramipril and amlodipine groups following discontinuation of the amlodipine intervention in September 2000.

Interventions

Participants were randomly assigned to receive amlodipine, 5 to 10 mg/d (n = 217), ramipril, 2.5 to 10 mg/d (n = 436), or metoprolol, 50 to 200 mg/d (n = 441), with other agents added to achieve 1 of 2 blood pressure goals.

Main Outcome Measures

The primary outcome measure was the rate of change in GFR; the main secondary outcome was a composite index of the clinical end points of reduction in GFR of more than 50% or 25 mL/min per 1.73 m², end-stage renal disease, or death.

Results

Among participants with a urinary protein to creatinine ratio of > 0.22 (corresponding approximately to proteinuria of more than 300 mg/d), the ramipril group had a 36% (2.02 [SE, 0.74] mL/min per 1.73 m²/y) slower mean decline in GFR over 3 years (P = 0.006) and a 48% reduced risk of the clinical end points vs the amlodipine group (95% confidence interval [CI] 20%-66%). In the entire cohort, there was no significant difference in mean GFR decline from baseline to 3 years between treatment groups (P = 0.38). However, compared with the amlodipine group, after adjustment for baseline covariates the ramipril group had a 38% reduced risk of clinical end points (95% CI, 13%-56%), a 36% slower mean decline in GFR after 3 months (P = 0.002), and less proteinuria (P < .001).

Conclusion

Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria.

---

### Which patients benefit the most from the perindopril / amlodipine combination [^2f4f12ae]. Journal of Hypertension (2011). Low credibility.

Fixed-dose combinations have been strongly endorsed by European guidelines for first-line and second-line treatment of hypertension. Among recommended combinations, that of an angiotensin-converting enzyme inhibitor and a calcium channel blocker stands out because the mechanisms of action of these two therapeutic classes are complementary, leading to enhanced efficacy. In the large multicentre ASCOT-BPLA trial, treatment based on the combination of amlodipine and perindopril significantly reduced the risk of cardiovascular and all-cause death, stroke, coronary events and procedures, new-onset diabetes, and new-onset renal impairment in a wide range of patients with hypertension and other cardiovascular risk factors, when compared with atenolol/thiazide-based therapy. The perindopril/amlodipine single-pill combination was developed based on guideline recommendations for combination treatment, the indications of each component, and ASCOT-BPLA trial data. Several studies in real-life settings show that a wide range of hypertensive patients, including everyday hypertensives with common risk factors, would benefit from the perindopril/amlodipine combination.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^8b41f0d8]. European Heart Journal (2024). Medium credibility.

Introduction

Blood pressure variability (BPV) is an important predictor of morbidity and mortality based on observational studies. In the blood pressure (BP)-lowering arm (LA) of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm (ASCOT-BPLA), an amlodipine-based treatment regimen reduced the incidence of cardiovascular (CV) outcomes and all-cause mortality compared with an atenolol-based regimen; but the small difference in mean BP between groups did not account for the observed differences in CV outcomes. Visit-to-visit systolic BPV was proposed as the determinant of the differences in outcomes between the amlodipine-based and atenolol-based treatment groups.

After 16-year long-term follow-up to mortality outcomes (without information on non-fatal events), there was a persistent reduction in stroke deaths in those formerly assigned to amlodipine-based treatment. There were numerically fewer CV deaths, but the difference was not significant when compared with those assigned to atenolol-based treatment. We now report non-fatal events based on electronic health records of hospital admissions and further mortality outcomes up to a total of 21-year follow-up. In addition, we also report the findings from the ASCOT-10 sub-study in which we collected data on treatment, self-reported outcomes, and BP control in a quarter of these subjects after the end of the trial. These evaluations helped improve our understanding of what happened to these subjects after the trial closure. Recently, our observations on stroke and dementia outcomes have been publishedbut with no attribution as to why the stroke protection existed beyond BP control. In the current analyses, we report the long-term impact of in-trial systolic BPV and mean BP on the long-term CV outcomes. We also report whether in the ASCOT legacy study the assignment to either of the original BP-lowering regimens conferred any long-term legacy benefits on fatal and non-fatal CV events or other new outcomes of interest, including the risk of atrial fibrillation and heart failure during the 21-year follow-up.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^ee08ec4a]. European Heart Journal (2024). Medium credibility.

Methods

The detailed ASCOT protocol, including study design, organization, clinical measurements, power calculations, recruitment rates, and baseline characteristics, has been published, and further information is available on the ASCOT website.

ASCOT trial blood pressure arm and participant profile

Briefly, ASCOT was designed to compare two antihypertensive treatment strategies, amlodipine to which perindopril was added as necessary (amlodipine-based) and atenolol, to which bendroflumethiazide was added as necessary (atenolol-based) — the BPLA. This population consisted of hypertensive men and women, aged between 40 and 79 years at randomization, with at least three additional risk factors for CV disease, but with no history of prior coronary heart disease (CHD) events, currently treated angina, stroke, or transient ischaemic attack (TIA) within 3 months prior to randomization. The primary outcome was non-fatal myocardial infarction (MI) and fatal CHD. Patients were originally recruited between February 1998 and May 2000. In the Nordic countries, participants were recruited from 686 family practices and in the UK and Ireland, most participants were referred from family practices to the regional centres for the study. Blood pressure was measured throughout the trial, initially 6 weeks after randomization, at 3 months, 6 months, and 6 monthly thereafter until the end of the trial. Nineteen thousand two hundred and fifty-seven participants were randomized to the BPLA. The BPLA was prematurely stopped in December 2004 (at the recommendation of the Data Safety and Monitoring Board) on account of significantly higher mortality amongst those allocated to the atenolol-based treatment compared with those on amlodipine-based treatment.

The study conformed to good clinical practice guidelines and the Declaration of Helsinki. The protocol and all subsequent amendments were reviewed and ratified by central and regional ethics review boards in the UK and by national ethics and statutory bodies in Ireland and the Nordic countries (Sweden, Denmark, Iceland, Norway, and Finland).

---

### Amlodipine besylate [^97318936]. FDA (2025). Medium credibility.

14.4 Effects in Documented Coronary Artery Disease

In PREVENT, 825 patients with angiographically documented coronary artery disease were randomized to amlodipine besylate tablets (5 to 10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction < 40%. Patients (76% males, 89% Caucasian, 93% enrolled at U.S. sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine besylate tablets (5 to 10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti-coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine besylate tablets and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540 to 0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 1). Effects in various subgroups are shown in Figure 2.

---

### Amlodipine (katerzia) [^33279f8a]. FDA (2023). Medium credibility.

14.4 Effects in Documented Coronary Artery Disease

In PREVENT, 825 patients with angiographically documented coronary artery disease were randomized to amlodipine (5–10 mg once daily) or placebo and followed for 3 years. Although the study did not show significance on the primary objective of change in coronary luminal diameter as assessed by quantitative coronary angiography, the data suggested a favorable outcome with respect to fewer hospitalizations for angina and revascularization procedures in patients with CAD.

CAMELOT enrolled 1318 patients with CAD recently documented by angiography, without left main coronary disease and without heart failure or an ejection fraction < 40%. Patients (76% males, 89% Caucasian, 93% enrolled at US sites, 89% with a history of angina, 52% without PCI, 4% with PCI and no stent, and 44% with a stent) were randomized to double-blind treatment with either amlodipine (5–10 mg once daily) or placebo in addition to standard care that included aspirin (89%), statins (83%), beta-blockers (74%), nitroglycerin (50%), anti‑coagulants (40%), and diuretics (32%), but excluded other calcium channel blockers. The mean duration of follow-up was 19 months. The primary endpoint was the time to first occurrence of one of the following events: hospitalization for angina pectoris, coronary revascularization, myocardial infarction, cardiovascular death, resuscitated cardiac arrest, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease. A total of 110 (16.6%) and 151 (23.1%) first events occurred in the amlodipine and placebo groups, respectively, for a hazard ratio of 0.691 (95% CI: 0.540–0.884, p = 0.003). The primary endpoint is summarized in Figure 1 below. The outcome of this study was largely derived from the prevention of hospitalizations for angina and the prevention of revascularization procedures (see Table 1). Effects in various subgroups are shown in Figure 2.

---

### Guidelines for antihypertensive treatment: an update after the ALLHAT study [^449c7722]. Journal of the American Society of Nephrology (2004). Low credibility.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Study, the largest double-blind, randomized trial in hypertensive patients, confirmed and strengthened the clinical relevance of thiazide diuretics in the treatment of hypertension but did not prove the superiority of these drugs. Its claim of the superiority of chlorthalidone was based on some secondary outcomes, principally represented by (1) an increased incidence of stroke in the doxazosin and lisinopril arms, an effect that might be explained by differences in systolic BP; (2) greater morbidity but not mortality for congestive heart failure (CHF) in the doxazosin, amlodipine, and lisinopril arms, a finding that might reflect poor accuracy in the diagnosis and/or especially the switching from diuretic treatment in 90% of patients. Moreover, the ALLHAT study has other limitations, and its conclusions are in contrast with data from overall controlled clinical trials indicating that given the same BP reduction, the benefit of different drug classes is similar. As to whether the ALLHAT study will influence ongoing guidelines concerning the choice of antihypertensive drugs, the answer is "yes" if interpretation of its data in favor of diuretics and cost of drugs become the preponderant considerations, as it was in recent JNC VII guidelines. However, the more liberal approach based on the choice of all available drug classes seems still to be valid, as is in the ESH-ESC guidelines, if the preponderant consideration is that the real benefit of antihypertensive therapy is due to efficient BP control and not to a particular benefit of a single drug class.

---

### Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients [^82d532b1]. The New England Journal of Medicine (2008). Excellent credibility.

Background

The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic.

Methods

In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.

Results

The baseline characteristics of the two groups were similar. The trial was terminated early after a mean follow-up of 36 months, when the boundary of the prespecified stopping rule was exceeded. Mean blood pressures after dose adjustment were 131.6/73.3 mm Hg in the benazepril-amlodipine group and 132.5/74.4 mm Hg in the benazepril-hydrochlorothiazide group. There were 552 primary-outcome events in the benazepril-amlodipine group (9.6%) and 679 in the benazepril-hydrochlorothiazide group (11.8%), representing an absolute risk reduction with benazepril-amlodipine therapy of 2.2% and a relative risk reduction of 19.6% (hazard ratio, 0.80, 95% confidence interval [CI] 0.72 to 0.90; P < 0.001). For the secondary end point of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, the hazard ratio was 0.79 (95% CI, 0.67 to 0.92; P = 0.002). Rates of adverse events were consistent with those observed from clinical experience with the study drugs.

Conclusions

The benazepril-amlodipine combination was superior to the benazepril-hydrochlorothiazide combination in reducing cardiovascular events in patients with hypertension who were at high risk for such events. (ClinicalTrials.gov number, NCT00170950.)

---

### Amlodipine besylate and valsartan (Amlodipine and valsartan) [^31d4de47]. FDA (2018). Low credibility.

14 CLINICAL STUDIES

Amlodipine and valsartan tablets were studied in 2 placebo-controlled and 4 active-controlled trials in hypertensive patients. In a double-blind, placebo-controlled study, a total of 1012 patients with mild-to-moderate hypertension received treatments of 3 combinations of amlodipine and valsartan (5/80, 5/160, 5/320 mg) or amlodipine alone (5 mg), valsartan alone (80, 160, or 320 mg) or placebo. All doses with the exception of the 5/320 mg dose were initiated at the randomized dose. The high dose was titrated to that dose after a week at a dose of 5/160 mg. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.

In a double-blind, placebo-controlled study, a total of 1246 patients with mild to moderate hypertension received treatments of 2 combinations of amlodipine and valsartan (10/160, 10/320 mg), or amlodipine alone (10 mg), valsartan alone (160 or 320 mg) or placebo. With the exception of the 10/320 mg dose, treatment was initiated at the randomized dose. The high dose was initiated at a dose of 5/160 mg and titrated to the randomized dose after 1 week. At week 8, the combination treatments were statistically significantly superior to their monotherapy components in reduction of diastolic and systolic blood pressures.

---

### Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2) [^2b0630ef]. JACC: Heart Failure (2013). Low credibility.

Objectives

This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy.

Background

A pre-specified subgroup analysis in an earlier, large-scale, placebo-controlled study suggested that amlodipine might reduce the risk for death in patients with heart failure due to a nonischemic cardiomyopathy.

Methods

To evaluate this hypothesis, 1654 patients with severe heart failure due to a nonischemic cardiomyopathy (ejection fraction < 30%) were randomly assigned to amlodipine (target dose: 10 mg/d) or placebo added to conventional therapy for heart failure for a median of 33 months.

Results

There were 278 deaths in the amlodipine group and 262 deaths in the placebo group (hazard ratio: 1.09; 95% confidence interval [CI]: 0.92 to 1.29; p = 0.33). The differences between the 2 groups in the risks for cardiovascular death and hospitalization were also not significant. When the results from patients with a nonischemic cardiomyopathy in both the earlier trial and in the current study were combined, there was no evidence of a favorable or unfavorable effect of amlodipine on mortality (hazard ratio: 0.97; 95% CI: 0.83 to 1.13; p = 0.66). Both trials, however, observed higher frequencies of peripheral edema and pulmonary edema and lower frequencies of uncontrolled hypertension and chest pain in patients treated with amlodipine.

Conclusions

These results of the current trial, viewed together with the results from the earlier study, indicate that amlodipine does not exert favorable effects on the clinical course of patients with heart failure, regardless of the presence or absence of underlying coronary artery disease. These findings indicate the need for great caution when striking benefits are observed in subgroups of patients or in trials not primarily designed to assess such effects.

---

### For debate: the 2023 European Society of Hypertension guidelines-cause for concern [^bdc2ee9c]. Journal of Hypertension (2024). Medium credibility.

Hypertension affects millions worldwide, and many organizations and learned societies have produced guidelines for its optimal management. Most agree that the best first-line therapy, when drug treatment is considered necessary, are the calcium channel blockers (CCBs), the angiotensin blockers or the thiazide-type diuretics.

Beta-blockers have long been considered best reserved for patients with concomitant comorbidities, where they have been shown to be effective. For example, they are used in patients with paroxysmal or persistent atrial fibrillation or symptomatic coronary heart disease. Also, they are indicated in patients who have recovered from a myocardial infarction or have heart failure.

Originally, the beta-blockers were equally ranked alongside the other drug classes. Things changed when two major long-term randomized controlled trials (RCTs), ASCOT-BPLA and LIFE showed that the patients receiving the beta-blocker based regimes suffered 25–30% more strokes than those receiving a CCB-based regime or an angiotensin receptor blocker (ARB) based regime. It is important to note that the inferiority of the beta-blockers at stroke prevention was not due to differences in blood pressure (BP) control during the follow-up period in both trials.

The independent investigator-led ASCOT-BPLA RCT compared amlodipine, with perindopril added if further BP reduction was required, (n = 9639) or atenolol with bendroflumethiazide added as necessary (n = 9618). The study was stopped early after a median 5.5-year follow-up due to 23% lower rates of stroke (3.4 vs. 4.4%), 11% lower mortality (7.7 vs. 8.5%) and 16% lower rates of total cardiovascular events and procedures (14.1 vs. 16.7%) in the amlodipine-based group. Of note, patients in the amlodipine group had a 30% lower risk of developing diabetes (11 vs. 16%), 35% fewer cases of peripheral artery disease (1.4 vs. 2.1%) and a 15% lower risk of renal impairment (4.2 vs. 4.9%, P < 0.05 for all). There was no difference in life-threatening arrhythmias, thus not demonstrating the benefits of this population's heart rate limiting and antiarrhythmic properties of BBs.

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^4131d573]. Journal of the American Heart Association (2018). Low credibility.

Introduction

Antihypertensive therapy is well established to reduce the adverse cardiovascular consequences of high blood pressure (BP). 1 The overall evidence supports that the degree of BP lowering is the major determinant of the health benefits. 1 Guidelines, therefore, emphasize the importance of controlling BP as the preeminent goal. 2, 3 In this regard, it is important to acknowledge that most hypertensive patients (eg, 75%) require ≥ 2 antihypertensive medications to achieve BP targets. 4 As such, the most germane issue to explore in guiding present‐day clinical practice is which combination of medications (rather than what single agent) provides optimal cardiovascular protection. 5 Although most patients in clinical trials were taking > 1 antihypertensive medication, 1 only the ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial was designed to investigate the comparative cardiovascular risk reductions derived from 2 prespecified combination regimens prescribed as initial therapy. 6 The study was terminated early (mean follow‐up, 36 months) because of the superiority of benazepril+amlodipine compared with benazepril+hydrochlorothiazide for preventing the primary composite outcome (hazard ratio [HR], 0.80; 95% confidence interval [CI] 0.72–0.90; P < 0.001). Subsequent analyses showed that this benefit occurred among patients with coronary artery disease 7 and diabetes mellitus, 8 was superior for preventing adverse renal outcomes, 9 and was not likely a consequence of subtle BP differences between groups (ambulatory BP monitoring). 10

---

### Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials [^bed06813]. BMJ (2011). Excellent credibility.

Angiotensin receptor blockers — cardioprotection v cerebroprotection

The 2004 results of the VALUE trial, in which the angiotensin receptor blocker valsartan produced a significant relative increase in myocardial infarction compared with amlodipine, has fuelled a debate on the safety of this class of drugs. In VALUE, those in the amlodipine arm had a modest but significantly lower blood pressure than those in the angiotensin receptor blockers arm (1.8 mm Hg systolic and 1.5 mm Hg diastolic) and a significantly lower blood pressure in the first three months, but whether this difference can explain the results has been contested.

Angiotensin II exerts most of its deleterious effects (vasoconstriction, increased cardiac contractility, renal tubular sodium reabsorption, cell proliferation, vascular and cardiac hypertrophy, inflammatory responses, and oxidative stress) via angiotensin I receptors, while the angiotensin II receptors counterbalance some of these effects. Angiotensin receptor blockers exert their action on angiotensin I receptors, which not only block the deleterious effect of angiotensin II but also results in overstimulation of angiotensin II receptors, probably resulting in antihypertrophic and antifibrotic effects. The angiotensin receptor blockers were thus thought to not only provide blockade of the renin-angiotensin system but also to allow for favourable stimulation of angiotensin II receptors. More recent studies, however, seem to suggest that chronic overstimulation of angiotensin II receptors might also exert a hypertrophic and antiangiogenic influence on cardiovascular tissues and that therefore the "long term consequences of ARB therapy might be less beneficial and could even be harmful in some circumstances". In addition, the pluripotential effects of angiotensin converting enzyme inhibitors have been attributed to upstream blockade of the renin-angiotensin axis, which also inhibits the degradation of kinins to inactive metabolites resulting in raised concentration of bioactive kinins such as bradykinin, which has been found to have several possible benefits such as anti-arrhythmic effects and reducing infarct size (mediated through ischaemic preconditioning and nitric oxide/prostacyclin related vascular protection). These pathophysiological mechanisms provide some mechanistic insight into the alleged inferiority of angiotensin receptor blockers compared with angiotensin converting enzyme inhibitors and potentially explain the adverse outcomes.

---

### Treatment of hypertension in patients ≥ 65 years of age: experience with amlodipine [^46a8607f]. Clinical Therapeutics (2000). Low credibility.

Background

Hypertension is a common finding in patients ≥ 65 years of age that contributes to cardiovascular morbidity and mortality, but many patients are untreated or their hypertension inadequately controlled. Recent randomized controlled studies have demonstrated the benefits of treating hypertension in the elderly.

Objective

This study was undertaken to assess the efficacy and tolerability of amlodipine, a long-acting calcium channel blocker, in elderly (≥ 65 years of age) patients with mild to moderate hypertension (diastolic blood pressure 95 to 114 mm Hg).

Methods

This was an open-label, multicenter, 10-week, general-practice study involving patients > 18 years of age. Patients with malignant or secondary hypertension or unstable angina were excluded, as were those who had experienced an acute myocardial infarction or stroke in the preceding 3 months or had been treated with an alpha-blocker in the preceding 6 months. Patients were assigned to 1 of 4 treatment schedules: amlodipine monotherapy or combination therapy and amlodipine given once daily in the morning or in the evening. Approximately 50% of patients would receive a morning dose, and approximately 80% would receive amlodipine as monotherapy. The paired t test was used to assess the significance of differences from baseline values, with significance set at P < 0.05.

Results

A total of 5135 patients received amlodipine and were included in the tolerability analysis. Of these, 3511 of 3628 patients (96.8%) < 65 years and 1471 of 1507 patients (97.6%) ≥ 65 years (including 336 of 349 [96.3%] ≥ 75 years) were included in the efficacy analysis. Significant reductions (P < 0.05) in blood pressure were noted in all groups after 4 and 8 weeks of treatment. The equivalence of efficacy in all age groups was seen in terms of reduction in blood pressure (reduction of 21/15 mm Hg in patients < 65 years of age, 25/16 mm Hg in those ≥ 65 years of age, and 26/17 mm Hg in those ≥ 75 years of age) compared with baseline. Therapy was successful in 2878 patients (82.0%) < 65 years of age, in 1238 patients (84.2%) ≥ 65 years of age, and in 284 patients (84.5%) ≥ 75 years of age. The incidence of adverse events was similar in all age groups (18.0%, < 65 years; 22.3%, ≥ 65 years; and 24.1%, ≥ 75 years), with no statistically significant differences between groups. Tolerability was rated as good or excellent in all patients, with no significant differences between groups.

Conclusions

Once-daily amlodipine was effective in the treatment of mild to moderate hypertension in this patient population and demonstrated a low frequency of adverse events, a high degree of tolerability, and improved well-being. Morning rather than evening dosing appeared to confer a slight advantage.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^380b0e85]. Open Heart (2016). Low credibility.

Objectives

Hypertension is well established as a major risk factor for cardiovascular disease. Although there is undeniable evidence to support the beneficial effects of antihypertensive therapy on morbidity and mortality, adequate blood pressure management still remains suboptimal. Research into the treatment of hypertension has produced a multitude of drug classes with different efficacy profiles. These agents include β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers and calcium channel blockers. One of the oldest groups of antihypertensives, the calcium channel blockers are a heterogeneous group of medications.

Methods

This review paper will focus on amlodipine, a dihydropyridine calcium channel blockers, which has been widely used for 2 decades.

Results

Amlodipine has good efficacy and safety, in addition to strong evidence from large randomised controlled trials for cardiovascular event reduction.

Conclusions

Amlodipine should be considered a first-line antihypertensive agent.

---

### Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension [^5db0b802]. American Journal of Hypertension (2002). Low credibility.

The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage 1 isolated systolic hypertension (ISH). After a 4-week placebo run-in phase, 150 patients were randomly assigned in a double-blind fashion to treatment with 5 mg of amlodipine (n = 48), 15 mg of chlorthalidone (n = 50), or placebo (n = 52). Patients who failed to meet the systolic blood pressure (BP) reduction goal by week 4 had their dose increased to 10 mg of amlodipine or 30 mg of chlorthalidone, and maintained at this increased dose for 12 weeks. Results showed a mean reduction (mean ± SD) in sitting systolic BP from baseline to the last treatment visit of -14.6 ± 12.2 mm Hg (95% confidence interval [CI] -18.2, -11.0), -14.0 ± 13.46 mm Hg (95% CI -17.8, -10.2), and -3.4 ± 11.83 mm Hg (95% CI -6.7, -0.1) for the amlodipine, chlorthalidone, and the placebo treatment groups, respectively. Both active treatments showed significantly greater reductions than the placebo group (P ≤ .001), but were not significantly different from each other. Sixty-seven percent of the amlodipine, 69% of the chlorthalidone, and 25% of the placebo-treated patients reached the protocol defined systolic BP goal (P = 0.001). Both active treatment groups showed a trend of better systolic BP response in older patients (≥ 65 years). Secondary efficacy measures including pulse pressure, standing systolic, diastolic, and the 24-h ambulatory BP were also statistically significantly improved for both active treatments at the end of treatment, except for chlorthalidone in standing diastolic BP. Adverse events that occurred during the study were as expected and were well tolerated. The results of this study support the efficacy and safety of amlodipine and chlorthalidone for the treatment of stage 1 ISH during 20 weeks of treatment.

---

### Amlodipine besylate and valsartan (Amlodipine and valsartan) [^fb5adfe2]. FDA (2018). Low credibility.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Studies with Amlodipine and Valsartan Tablets:

Amlodipine and valsartan tablets have been evaluated for safety in over 2600 patients with hypertension; over 1440 of these patients were treated for at least 6 months and over 540 of these patients were treated for at least 1 year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.

The hazards [see Warnings and Precautions (5)] of valsartan are generally independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter.

The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In placebo-controlled clinical trials, discontinuation due to side effects occurred in 1.8% of patients in the amlodipine and valsartan tablet-treated patients and 2.1% in the placebo-treated group. The most common reasons for discontinuation of therapy with amlodipine and valsartan tablets were peripheral edema (0.4%), and vertigo (0.2%).

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^49adaf42]. Journal of the American Heart Association (2018). Low credibility.

Background

The(Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided greater cardiovascular risk reduction among high‐risk hypertensive patients. Few trials have evaluated the effect of prior antihypertensive therapy used among participants on the study outcomes.

Methods and Results

In a post hoc observational analysis, we examined the characteristics of the drug regimens taken before trial enrollment in the context of the primary composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization). In the "primary subgroup" (n = 4475), patients previously taking any renin‐angiotensin system blockade plus either a diuretic or a calcium channel blocker alone or as part of their antihypertensive regimen, there were 206 of 2193 (9.4%) versus 281 of 2282 (12.3%) primary composite events among those randomized to combination therapy involving amlodipine versus hydrochlorothiazide, respectively (adjusted Cox proportional hazard ratio, 0.74; 95% confidence interval, 0.62–0.89; P = 0.0015). All other participants (n = 6975) previously taking any antihypertensive regimen not included in the primary subgroup also benefited from randomization to amlodipine plus benazepril (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72–0.98; P = 0.024). Outcomes among most other subgroups, including patients previously taking lipid‐lowering medications or dichotomized by prior blood pressure control status, showed similar results.

Conclusions

When combined with an angiotensin‐converting enzyme inhibitor, amlodipine provides cardiovascular risk reduction superior to hydrochlorothiazide, largely regardless of prior medication use. These findings add further support for the initial use of this combination regimen among high‐risk hypertensive patients.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^7559a5a0]. European Heart Journal (2024). Medium credibility.

A team of two physicians independently adjudicated all deaths, using pre-specified criteria that were consistent with the definitions used during the in-trial period. Outcomes for non-fatal events were obtained from electronic hospital records with previously validated code lists and classified them to the outcomes consistent with the original trial outcomes.

Our objectives were first, to determine the impact of in-trial systolic BPV and mean BP on the post-trial long-term CV outcome (a landmark analysis) and second, to compare the time to first occurrence of the following CV outcomes between those assigned to amlodipine-based and atenolol-based treatment: fatal and non-fatal stroke, non-fatal MI and fatal CHD, total coronary events, fatal and non-fatal heart failure, total CV events and procedures, atrial fibrillation, CV mortality, and all-cause mortality. Definitions for the various composite endpoints are available on.

In 2011–12, after 6 years of trial closure and as a part of the ASCOT-10 study, a subgroup of surviving participants (n = 2156) was identified from 18 regional centres that had participated in the original trial in the UK and invited to complete a questionnaire on health and current medications. Of these, a further subgroup (n = 414) was recalled to the clinic for BP measurement and routine blood chemistry.

---

### Amlodipine besylate and atorvastatin calcium (Caduet) [^3a75032f]. FDA (2025). Medium credibility.

Amlodipine

Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine was well tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (N = 1730) at doses up to 10 mg to placebo (N = 1250), discontinuation of amlodipine because of adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most commonly reported side effects more frequent than placebo are dizziness and edema. The incidence (%) of side effects that occurred in a dose related manner are as follows:

Other adverse reactions that were not clearly dose related but were reported at an incidence greater than 1.0% in placebo-controlled clinical trials include the following:

Edema, flushing, palpitations, and somnolence appear to be more common in women than in men.

The following events occurred in < 1% but > 0.1% of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:

---

### Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial [^c63213f8]. Journal of Hypertension (2006). Low credibility.

Background

In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pressure reductions were significantly more pronounced with amlodipine. Stroke incidence was non-significantly, and myocardial infarction was significantly lower in the amlodipine-based regimen, whereas cardiac failure was non-significantly lower on valsartan.

Objectives

The study protocol specified additional analyses of the primary endpoint according to: sex; age; race; geographical region; smoking status; type 2 diabetes; total cholesterol; left ventricular hypertrophy; proteinuria; serum creatinine; a history of coronary heart disease; a history of stroke or transient ischemic attack; and a history of peripheral artery disease. Additional subgroups were isolated systolic hypertension and classes of antihypertensive agents used immediately before randomization.

Methods

The 15,245 hypertensive patients participating in VALUE were divided into subgroups according to baseline characteristics. Treatment by subgroup interaction analyses were carried out by a Cox proportional hazard model. Within each subgroup, treatment effects were assessed by hazard ratios and 95% confidence intervals.

Results

For cardiac mortality and morbidity, the only significant subgroup by treatment interaction was of sex (P = 0.016), with the hazard ratio indicating a relative excess of cardiac events with valsartan treatment in women but not in men, but SBP differences in favour of amlodipine were distinctly greater in women. No other subgroup showed a significant difference in the composite cardiac outcome between valsartan and amlodipine-based treatments. For secondary endpoints, a sex-related significant interaction was found for heart failure (P < 0.0001), with men but not women having a lower incidence of heart failure with valsartan.

Conclusion

As in the whole VALUE cohort, in no subgroup of patients were there differences in the incidence of the composite cardiac endpoint with valsartan and amlodipine-based treatments, despite a greater blood pressure decrease in the amlodipine group. The only exception was sex, in which the amlodipine-based regimen was more effective than valsartan in women, but not in men, whereas the valsartan regimen was more effective in preventing cardiac failure in men than in women.

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^9d87969e]. Journal of the American Heart Association (2018). Low credibility.

Background

The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided greater cardiovascular risk reduction among high-risk hypertensive patients. Few trials have evaluated the effect of prior antihypertensive therapy used among participants on the study outcomes.

Methods and Results

In a post hoc observational analysis, we examined the characteristics of the drug regimens taken before trial enrollment in the context of the primary composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization). In the "primary subgroup" (n = 4475), patients previously taking any renin-angiotensin system blockade plus either a diuretic or a calcium channel blocker alone or as part of their antihypertensive regimen, there were 206 of 2193 (9.4%) versus 281 of 2282 (12.3%) primary composite events among those randomized to combination therapy involving amlodipine versus hydrochlorothiazide, respectively (adjusted Cox proportional hazard ratio, 0.74; 95% confidence interval, 0.62–0.89; P = 0.0015). All other participants (n = 6975) previously taking any antihypertensive regimen not included in the primary subgroup also benefited from randomization to amlodipine plus benazepril (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72–0.98; P = 0.024). Outcomes among most other subgroups, including patients previously taking lipid-lowering medications or dichotomized by prior blood pressure control status, showed similar results.

Conclusions

When combined with an angiotensin-converting enzyme inhibitor, amlodipine provides cardiovascular risk reduction superior to hydrochlorothiazide, largely regardless of prior medication use. These findings add further support for the initial use of this combination regimen among high-risk hypertensive patients.

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^94e21f06]. Journal of the American Heart Association (2018). Low credibility.

Methods

The overall design and methods of the ACCOMPLISH trial have been previously described. 6 The institutional review boards or ethics committees of each participating site approved the protocol, as described in the primary article. 6 The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. In brief, the ACCOMPLISH trial was an international (5 countries), multicenter (n = 548), double‐blind, randomized, clinical outcome trial of 11 056 patients with hypertension at high risk for cardiovascular disease. The primary outcome was time to first composite event (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) compared between treatment limbs (benazepril+amlodipine versus benazepril+hydrochlorothiazide). In this post hoc observational analysis, we aimed to evaluate the effect of prior medication regimens on the primary study outcome. Before undertaking the analyses, we a priori defined the primary subgroup as patients previously taking a regimen similar to either randomized treatment subsequently allocated in the trial. This included individuals taking an RAS blocker (any angiotensin‐converting enzyme inhibitor [ACEI] or angiotensin receptor blocker) plus either a thiazide‐like diuretic or CCB. The 2 antihypertensive medications could be taken alone (ie, no additional BP medications) or as part of a larger regimen (≥ 3 drugs in total), including any supplementary BP‐lowering medications (eg, β or α blockers). We began the series of analyses with and highlighted the presentation of our findings in this primary subgroup because we believed the results from these patients would yield the overall most clinically relevant information. These findings specifically inform healthcare providers the sum benefits together of maintaining an RAS blocker/CCB regimen if already taking it and switching to this regimen among patients taking an RAS blocker/diuretic regimen. Subsequent analyses further evaluated the individual benefits in each of these subgroups alone, along with several other groups with a viable sample size.

---

### Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial [^856fd113]. Lancet (2004). Excellent credibility.

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension. But inequalities in blood pressure, favouring amlodipine, throughout the multiyear trial precluded comparison of outcomes. A technique of serial median matching, applied at 6 months when treatment adjustments intended to achieve control of blood pressure were complete, created 5006 valsartan-amlodipine patient pairs matched exactly for systolic blood pressure, age, sex, and the presence or absence of previous coronary disease, stroke, or diabetes. Subsequent combined cardiac events, myocardial infarction, stroke, and mortality were almost identical in the two cohorts, but admission to hospital for heart failure was significantly lower with valsartan. Reaching blood pressure control (systolic < 140 mm Hg) by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^35b62a0b]. European Heart Journal (2024). Medium credibility.

It is now evident from the long-term follow-up of ASCOT that, although BP control observed during the trial was a predictor of long-term CV outcomes, visit-to-visit systolic BPV was a stronger predictor of these events. We have also demonstrated that increased systolic BPV is an important determinant of CV outcome, even in those who, according to many guidelines, have controlled SBP to < 140 mmHg. In these analyses, more than half of all long-term CV events occurred in this group of participants, who represented 44% of the trial population and who would hitherto not have been considered for additional therapeutic intervention. It is apparent that amongst those who have controlled BPs for a period of time (5 years), the systolic BPV of 13 mmHg or more is associated with significantly higher CV and CHD morbidity and mortality.

We previously reported that after 16 years of follow-up, on average 10.5 years after the closure of the trial, there was a persistent reduction in stroke mortality in favour of those participants formerly assigned amlodipine-based treatment compared with atenolol-based treatment. In the current analyses, we have extended these observations on subjects who have been followed up for up to 21 years and incorporated extensive findings from electronic records of hospital admissions for CV events together with accumulated data on mortality.

A persistent benefit on stroke, all coronary events, and all CV events were seen in those patients formerly assigned to amlodipine-based treatment. These proportional reductions in events were slightly less than those recorded during the original trial and probably accounted for by the extensive crossover of treatments in the post-trial period between the two formerly randomized groups. There was also a reduction in the incidence of atrial fibrillation associated with amlodipine-based treatment which, together with the reduction in BP variability, were likely explanations for the persistence of beneficial effects on the risk of stroke (Structured Graphical Abstract).

---

### Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview [^8edec961]. Hypertension (2007). Low credibility.

In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy. The analysis included 12 trials of 94 338 patients. The analysis of trials involving an amlodipine group showed that amlodipine provided more protection against stroke and myocardial infarction than other antihypertensive drugs, including angiotensin receptor blockers (-19%, P < 0.0001 and -7%, P = 0.03) and placebo (-37%, P = 0.06 and -29%, P = 0.04). The analysis of trials involving an angiotensin receptor blocker group showed contrasting results between trials versus amlodipine and trials versus other antihypertensive drugs for stroke (+19% versus -25%; P < 0.0001) and myocardial infarction (+21% versus +1%; P = 0.03). The results of 3 trials comparing an angiotensin receptor blocker with placebo were neutral (P ≥ 0.14). The within-trial between-group difference in achieved systolic pressure ranged from -1.1 to +4.7 mm Hg for trials involving an amlodipine group and from -2.8 to +4.0 mm Hg for trials involving an angiotensin receptor blocker group. The metaregression analysis correlating odds ratios with blood pressure differences showed a negative relationship (regression coefficients: -3% to -8%), which reached statistical significance (regression coefficient: -6%; P = 0.01) for stroke in trials involving an amlodipine group. In conclusion, blood pressure differences largely accounted for cardiovascular outcome.

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^dd396d61]. Journal of the American Heart Association (2018). Low credibility.

Table 1
Characteristics of the Participants in the Main Subgroups (Total N = 11 450)

The following results are from the individual subgroup analyses. In the primary subgroup, there were 206 of 2193 (9.4%) composite study events among individuals randomized to benazepril+amlodipine versus 281 of 2282 (12.3%) among those allocated to benazepril+hydrochlorothiazide (adjusted HR, 0.74; 95% CI, 0.62–0.89; P = 0.0015) (Figure 1). In all other participant subgroups, those assigned to benazepril+amlodipine (adjusted HR, 0.84; 95% CI, 0.72–0.98; P = 0.024) also benefited (Figure 2). Confining the analyses to a "limited primary subgroup", including individuals previously taking a 2‐drug regimen consisting of only an RAS blocker plus either a thiazide‐like diuretic or CCB (ie, no additional antihypertensive agent of any class in their regimen), yielded similar results. In this limited primary subgroup (n = 2266), there were 97 of 1140 (8.5%) composite study events among individuals randomized to benazepril+amlodipine versus 117 of 1126 (10.4%) among those allocated to benazepril+hydrochlorothiazide (adjusted HR, 0.80; 95% CI, 0.61–1.04; P = 0.099). Given the similar HR to that of the primary subgroup, the borderline nonsignificant P value is likely attributable to a smaller sample size. All other participants not in the limited primary subgroup (n = 9184) also benefited from assignment to benazepril+amlodipine (HR, 0.80; 95% CI, 0.70–0.91; P = 0.0006). Controlling for achieved BP levels at 6 months into the trial did not substantively alter the results for any of the previously described subgroups.

---

### Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial [^ff6d62ef]. Lancet (2005). Excellent credibility.

Background

The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and beta blockers used. For a given reduction in blood pressure, some suggested that newer agents would confer advantages over diuretics and beta blockers. Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril.

Methods

We did a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension who were aged 40–79 years and had at least three other cardiovascular risk factors. Patients were assigned either amlodipine 5–10 mg adding perindopril 4–8 mg as required (amlodipine-based regimen; n = 9639) or atenolol 50–100 mg adding bendroflumethiazide 1.25–2.5 mg and potassium as required (atenolol-based regimen; n = 9618). Our primary endpoint was non-fatal myocardial infarction (including silent myocardial infarction) and fatal CHD. Analysis was by intention to treat.

Findings

The study was stopped prematurely after 5.5 years' median follow-up and accumulated in total 106 153 patient-years of observation. Though not significant, compared with the atenolol-based regimen, fewer individuals on the amlodipine-based regimen had a primary endpoint (429 vs 474; unadjusted HR 0.90, 95% CI 0.79–1.02, p = 0.1052), fatal and non-fatal stroke (327 vs 422; 0.77, 0.66–0.89, p = 0.0003), total cardiovascular events and procedures (1362 vs 1602; 0.84, 0.78–0.90, p < 0.0001), and all-cause mortality (738 vs 820; 0.89, 0.81–0.99, p = 0.025). The incidence of developing diabetes was less on the amlodipine-based regimen (567 vs 799; 0.70, 0.63–0.78, p < 0.0001).

Interpretation

The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen. On the basis of previous trial evidence, these effects might not be entirely explained by better control of blood pressure, and this issue is addressed in the accompanying article. Nevertheless, the results have implications with respect to optimum combinations of antihypertensive agents.

---

### Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine [^cbcaa982]. Journal of Human Hypertension (2007). Low credibility.

In the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the risk of new-onset diabetes was reported to be 23% lower among patients initiating therapy with valsartan versus amlodipine. The objective of our study was to examine whether this finding is generalizable to 'real-world' clinical practice. A retrospective cohort design and a large US health insurance database were employed for analyses. Study subjects included all hypertensive patients, aged ≥ 35 years, who were free from diabetes and who initiated treatment with valsartan (n = 9999) or amlodipine (n = 18 698) between January 1999 and March 2005. Unadjusted absolute risks of diabetes were 21.4 (95% confidence interval (CI) 18.9–24.3) and 26.3 (95% CI 24.3–28.3) per 1000 patient-years for valsartan and amlodipine, respectively; the corresponding relative risk (RR) for valsartan was 0.82 (95% CI 0.70–0.94). Multivariate analyses - controlling for age, sex, presence of hypercholesterolemia, cardiovascular disease and kidney disease, and pretreatment medical care expenditures - yielded similar results (RR = 0.79, 95% CI 0.68–0.92). Our study thus corroborates the finding from VALUE that diabetes risk is lower for patients who receive valsartan versus amlodipine, and extends this finding to a 'real-world' setting.

---

### Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial [^23433dd5]. JAMA (2004). Excellent credibility.

Context

The effect of antihypertensive drugs on cardiovascular events in patients with coronary artery disease (CAD) and normal blood pressure remains uncertain.

Objective

To compare the effects of amlodipine or enalapril vs placebo on cardiovascular events in patients with CAD.

Design, Setting, and Participants

Double-blind, randomized, multicenter, 24-month trial (enrollment April 1999-April 2002) comparing amlodipine or enalapril with placebo in 1991 patients with angiographically documented CAD (> 20% stenosis by coronary angiography) and diastolic blood pressure < 100 mm Hg. A substudy of 274 patients measured atherosclerosis progression by intravascular ultrasound (IVUS).

Interventions

Patients were randomized to receive amlodipine, 10 mg; enalapril, 20 mg; or placebo. IVUS was performed at baseline and study completion.

Main Outcome Measures

The primary efficacy parameter was incidence of cardiovascular events for amlodipine vs placebo. Other outcomes included comparisons of amlodipine vs enalapril and enalapril vs placebo. Events included cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, coronary revascularization, hospitalization for angina pectoris, hospitalization for congestive heart failure, fatal or nonfatal stroke or transient ischemic attack, and new diagnosis of peripheral vascular disease. The IVUS end point was change in percent atheroma volume.

Results

Baseline blood pressure averaged 129/78 mm Hg for all patients; it increased by 0.7/0.6 mm Hg in the placebo group and decreased by 4.8/2.5 mm Hg and 4.9/2.4 mm Hg in the amlodipine and enalapril groups, respectively (P < .001 for both vs placebo). Cardiovascular events occurred in 151 (23.1%) placebo-treated patients, in 110 (16.6%) amlodipine-treated patients (hazard ratio [HR], 0.69; 95% CI, 0.54–0.88 [P = 0.003]), and in 136 (20.2%) enalapril-treated patients (HR, 0.85; 95% CI, 0.67–1.07 [P = 0.16]. Primary end point comparison for enalapril vs amlodipine was not significant (HR, 0.81; 95% CI, 0.63–1.04 [P = 0.10]). The IVUS substudy showed a trend toward less progression of atherosclerosis in the amlodipine group vs placebo (P = 0.12), with significantly less progression in the subgroup with systolic blood pressures greater than the mean (P = 0.02). Compared with baseline, IVUS showed progression in the placebo group (P < .001), a trend toward progression in the enalapril group (P = 0.08), and no progression in the amlodipine group (P = 0.31). For the amlodipine group, correlation between blood pressure reduction and progression was r = 0.19, P = 0.07.

Conclusions

Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events. Directionally similar, but smaller and nonsignificant, treatment effects were observed with enalapril. For amlodipine, IVUS showed evidence of slowing of atherosclerosis progression.

---

### Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the anglo-scandinavian cardiac outcomes trial (ASCOT) legacy study: 16-year follow-up results of a randomised factorial trial [^880c78c4]. Lancet (2018). Excellent credibility.

Background

In patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.

Methods

ASCOT was a multicentre randomised trial with a 2×2 factorial design. UK-based patients with hypertension were followed up for all-cause and cardiovascular mortality for a median of 15.7 years (IQR 9.7–16.4 years). At baseline, all patients enrolled into the blood pressure-lowering arm (BPLA) of ASCOT were randomly assigned to receive either amlodipine-based or atenolol-based blood pressure-lowering treatment. Of these patients, those who had total cholesterol of 6.5 mmol/L or lower and no previous lipid-lowering treatment underwent further randomisation to receive either atorvastatin or placebo as part of the lipid-lowering arm (LLA) of ASCOT. The remaining patients formed the non-LLA group. A team of two physicians independently adjudicated all causes of death.

Findings

Of 8580 UK-based patients in ASCOT, 3282 (38.3%) died, including 1640 (38.4%) of 4275 assigned to atenolol-based treatment and 1642 (38.1%) of 4305 assigned to amlodipine-based treatment. 1768 of the 4605 patients in the LLA died, including 903 (39.5%) of 2288 assigned placebo and 865 (37.3%) of 2317 assigned atorvastatin. Of all deaths, 1210 (36.9%) were from cardiovascular-related causes. Among patients in the BPLA, there was no overall difference in all-cause mortality between treatments (adjusted hazard ratio [HR] 0.90, 95% CI 0.81–1.01, p = 0.0776]), although significantly fewer deaths from stroke (adjusted HR 0.71, 0.53–0.97, p = 0.0305) occurred in the amlodipine-based treatment group than in the atenolol-based treatment group. There was no interaction between treatment allocation in the BPLA and in the LLA. However, in the 3975 patients in the non-LLA group, there were fewer cardiovascular deaths (adjusted HR 0.79, 0.67–0.93, p = 0.0046) among those assigned to amlodipine-based treatment compared with atenolol-based treatment (p = 0.022 for the test for interaction between the two blood pressure treatments and allocation to LLA or not). In the LLA, significantly fewer cardiovascular deaths (HR 0.85, 0.72–0.99, p = 0.0395) occurred among patients assigned to statin than among those assigned placebo.

Interpretation

Our findings show the long-term beneficial effects on mortality of antihypertensive treatment with a calcium channel blocker-based treatment regimen and lipid-lowering with a statin: patients on amlodipine-based treatment had fewer stroke deaths and patients on atorvastatin had fewer cardiovascular deaths more than 10 years after trial closure. Overall, the ASCOT Legacy study supports the notion that interventions for blood pressure and cholesterol are associated with long-term benefits on cardiovascular outcomes.

Funding

Pfizer.

---

### Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006 [^e3e16374]. The Journal of Heart and Lung Transplantation (2006). Medium credibility.

Calcium channel blocker (amlodipine) — hypertension control in heart failure: Although most calcium channel blockers have been associated with excess cardiac risk, this "has not been the case with amlodipine", and "the use of amlodipine may be considered if hypertension cannot otherwise be controlled".

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^5f55b260]. European Heart Journal (2024). Medium credibility.

Background and Aims

Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.

Methods

Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine ± perindopril-based and 4275 to atenolol ± diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using > 100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.

Results

Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10mmHg, 1.14 [95% confidence interval (CI) 1.10–1.17], P < .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5mmHg 1.22 (95% CI 1.18–1.26), P < .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72–0.93), P = 0.003], total CV events [HR 0.93 (95% CI 0.88–0.98), P = 0.008], total coronary events [HR 0.92 (95% CI 0.86–0.99), P = 0.024], and atrial fibrillation [HR 0.91 (95% CI 0.83–0.99), P = 0.030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82–1.01), P = 0.073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.

Conclusions

Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.

---

### Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension [^65b75bba]. Clinical Therapeutics (2007). Low credibility.

Background

Amlodipine besylate has been used in Korea for the treatment of hypertension for > 17 years, with well-established efficacy and tolerability. Amlodipine camsylate is a newer formulation developed for generic use. It has been assessed in terms of physical stability and pharmacokinetic and pharmacodynamic properties and been found to be effective in lowering blood pressure in preclinical and Phase I and II trials. However, to date, no studies have compared the clinical effectiveness of amlodipine camsylate and amlodipine besylate in treating hypertension.

Objective

This study was designed to determine the effectiveness and tolerability of amlodipine camsylate compared with amlodipine besylate in Korean patients with mild to moderate hypertension.

Methods

This Phase III, 8-week, prospective, randomized, double-blind, parallel-group study was conducted in 13 cardiology centers across the Republic of Korea. Male and female Korean patients aged 18 to 75 years having uncomplicated, mild to moderate, essential hypertension (sitting diastolic blood pressure [SiDBP] 90- < 110 mm Hg) and receiving no antihypertensives in the 2 weeks before randomization were eligible. Patients were randomly assigned to receive oral treatment with amlodipine camsylate or amlodipine besylate. For the first 4 weeks, patients received amlodipine 5 mg QD (morning). After 4 weeks, if either blood pressure was ≥ 140/ ≥ 90 mm Hg or SiDBP had not decreased by ≥ 10 mm Hg from baseline, the dose of amlodipine was increased to 10 mg QD for 4 weeks. Trough blood pressure and heart rate were measured in duplicate with the patient in the sitting position at each clinic visit (baseline [week 0] and weeks 4 and 8 of treatment); mean values were calculated and recorded. At weeks 4 and 8, tolerability was assessed using history taking and laboratory analysis, and compliance was assessed using pill counts. The primary end point was change from baseline in SiDBP at week 8. Secondary end points were change from baseline in sitting systolic blood pressure (SiSBP) at week 8 in the total population and in the subgroup of patients who had previously received antihypertensive treatment versus those who had not.

Results

A total of 189 patients were enrolled (mean age, 53 years; 105 women, 84 men; mean body weight, 65.8 kg). One patient in the amlodipine camsylate group dropped out of the study at week 0 of treatment (this patient did not use any study medication) and was excluded from the modified intent-to-treat (ITT) analysis. Thus, 188 patients were treated and included in the ITT analysis (94 patients per treatment group; ITT analysis); 161 patients were included in the perprotocol (PP) analysis (n = 80 for amlodipine camsylate, n = 81 for amlodipine besylate) (14 patients in the amlodipine camsylate group and 13 patients in the amlodipine besylate group were excluded from the PP analysis due to consistent withdrawal or protocol violation). Mean (SD) SiSBP and SiDBP were significantly decreased from baseline in both groups (amlodipine camsylate, from 146.7 [12.3]/96.6 [5.4] to 127.9 [14.8]/83.4 [7.7] mm Hg [both, P < 0.001]; amlodipine besylate, from 146.8 [12.8]/96.7 [5.1] to 128.0 [10.1]/83.8 [7.5] mm Hg [both, P < 0.001]). The differences in SiSBP/SiDBP between the 2 groups at week 8 were not significant. The SiDBP response rates in the subgroups that had and had not been previously treated with antihypertensives were statistically similar (56/69 [81.2%] and 83/92 [90.2%], respectively). The prevalences of clinical adverse events (AEs) were not significantly different between the 2 treatment groups (amlodipine camsylate, 27.3%; amlodipine besylate, 28.7%). The most common AEs were dizziness and dyspnea (both in 3/94 [3.2%] and 1/94 [1.1%] patients who received amlodipine camsylate and amlodipine besylate, respectively).

Conclusion

The effectiveness and tolerability of amlodipine camsylate were not significantly different from those of amlodipine besylate in these Korean adults with mild to moderate hypertension.

---

### Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials [^1e179ad3]. BMJ (2011). Excellent credibility.

Introduction

The provocative editorial by Verma and Strauss in the BMJ in 2004stating that angiotensin receptor blockers "may increase myocardial infarction — and patients may need to be told" led to extensive scrutiny of outcome data with these drugs. This controversy was a direct fallout from the publication of the valsartan antihypertensive long term use evaluation (VALUE) trial, in which the primary hypothesis stated that "in hypertensive patients at high cardiovascular risk, for the same level of blood pressure control, valsartan will be more effective than amlodipine in reducing cardiac morbidity and mortality". Unexpectedly, there was a significant 19% relative increase in the prespecified secondary outcome measure of myocardial infarction in the valsartan arm compared with the amlodipine arm.

In 2008 a Cochrane Collaboration review found angiotensin receptor blockers to be as effective as angiotensin converting enzyme inhibitors at reducing blood pressure, though the effect was modest. The blood pressure lowering treatment trialists' collaboration has shown similar blood pressure dependent effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers for the risk of stroke, coronary heart disease, and heart failure. The authors cautioned, however, that there was evidence of a blood pressure independent effect on the risk of major coronary disease events only for angiotensin converting enzyme inhibitors, not for angiotensin receptor blockers. In addition, more recent trials like the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), a thorough, double blind prospective randomised trial, documented equal outcome efficacy of an angiotensin receptor blocker (telmisartan) and an angiotensin converting enzyme inhibitor in a high risk population, though there was a trend towards better prevention of stroke in the angiotensin receptor blocker arm and towards better prevention of coronary artery disease in the angiotensin converting enzyme inhibitor (ramipril) arm.

We evaluated the risk of cardiovascular and other outcomes with angiotensin receptor blockers in general and tested the hypothesis of increased risk of myocardial infarction with angiotensin receptor blockers found in previous studies and analyses.

---

### Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril [^591ab355]. JAMA (2005). Excellent credibility.

Context

Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs).

Objective

To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups.

Design, Setting, and Participants

Prespecified subgroup analysis of ALLHAT, a randomized, double-blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33,357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor.

Interventions

Antihypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs) less than 140/90 mm Hg.

Main Outcome Measures

The primary outcome was combined fatal coronary heart disease (CHD) or nonfatal myocardial infarction (MI), analyzed by intention-to-treat. Secondary outcomes included all-cause mortality, stroke, combined CVD (CHD death, nonfatal MI, stroke, angina, coronary revascularization, heart failure [HF], or peripheral vascular disease), and end-stage renal disease.

Results

No significant difference was found between treatment groups for the primary CHD outcome in either racial subgroup. For amlodipine vs chlorthalidone only, HF was the only prespecified clinical outcome that differed significantly (overall: relative risk [RR], 1.37; 95% confidence interval [CI] 1.24–1.51; blacks: RR, 1.46; 95% CI, 1.24–1.73; nonblacks: RR, 1.32; 95% CI, 1.17–1.49; P < .001 for each comparison) with no difference in treatment effects by race (P = 0.38 for interaction). For lisinopril vs chlorthalidone, results differed by race for systolic BP (greater decrease in blacks with chlorthalidone), stroke, and combined CVD outcomes (P < .001, P = 0.01, and P = 0.04, respectively, for interactions). In blacks and nonblacks, respectively, the RRs for stroke were 1.40 (95% CI, 1.17–1.68) and 1.00 (95% CI, 0.85–1.17) and for combined CVD were 1.19 (95% CI, 1.09–1.30) and 1.06 (95% CI, 1.00–1.13). For HF, the RRs were 1.30 (95% CI, 1.10–1.54) and 1.13 (95% CI, 1.00–1.28), with no significant interaction by race. Time-dependent BP adjustment did not significantly alter differences in outcome for lisinopril vs chlorthalidone in blacks.

Conclusions

In blacks and nonblack subgroups, rates were not lower in the amlodipine or lisinopril groups than in the chlorthalidone group for either the primary CHD or any other prespecified clinical outcome, and diuretic-based treatment resulted in the lowest risk of heart failure. While the improved outcomes with chlorthalidone were more pronounced for some outcomes in blacks than in nonblacks, thiazide-type diuretics remain the drugs of choice for initial therapy of hypertension in both black and nonblack hypertensive patients.

---

### Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients [^6d907ad9]. Nephrology, Dialysis, Transplantation (2008). Low credibility.

Discussion

Our findings show that amlodipine non-significantly reduces the primary endpoint, i.e. all-cause mortality, by 35% in hypertensive patients with chronic kidney disease stage 5. Although it did not reach statistical significance, it may, however, be clinically relevant considering the excess mortality in these high-risk patients. The primary endpoint had been designed assuming a mortality of 40% in 30 months whereas in the present study, mortality was 15%. Furthermore, many more patients than expected underwent kidney transplantation during the course of the study.

However, this prospective, randomized study for the first time demonstrated that amlodipine (10 mg once daily) reduces the secondary composite endpoint that included mortality from any cause, cardiac event including myocardial infarction, need for coronary angioplasty or coronary bypass surgery, ischaemic stroke and peripheral vascular disease with the need for amputation or angioplasty in these patients with a high risk of macrovascular events. The use of amlodipine was associated with a significant reduction of the secondary composite endpoint by 47% in hypertensive patients with chronic kidney disease stage 5.

The post hoc definition of the secondary composite endpoint considered the high risk of macrovascular events in these patients with chronic kidney disease stage 5 and respective established outcome definitions reported in previous studies in these patients. This secondary composite endpoint was significantly reduced by administration of amlodipine. The favourable effect of the calcium channel blocker amlodipine should be compared to the reported effects of other treatment modalities in patents with chronic kidney disease stage 5. A recent study indicated that lipid-lowering drugs had no statistically significant effect on the composite endpoint of cardiovascular death, non-fatal myocardial infarction and stroke in diabetic patients with chronic kidney disease stage 5.

According to the study protocol, patients were treated according to the established treatment guidelines and > 50% of the patients received angiotensin-converting enzyme inhibitors or ß-blockers. Although the use of additional antihypertensive drugs was permitted in the study protocol, the cause of different systolic blood pressure values during the course of the study remains unclear. It is noteworthy that hypotensive episodes were observed more frequently in the placebo group compared to the amlodipine group (13% versus 7%), although that difference did not reach a statistical significance. Patients in the amlodipine group developed lower systolic blood pressure during the study period. The beneficial effects of amlodipine to prevent the secondary composite endpoint might be attributed to its antihypertensive effects. That finding is in accordance with results from the VALUE trial showing a beneficial effect of amlodipine versus valsartan due to low blood pressure.

---

### Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial [^d81f8c8e]. European Heart Journal (2024). Medium credibility.

Discussion

In the companion paper to the original publication of the outcomes of ASCOT-BPLA, we concluded that the small differences in mean BP between the two treatment arms during the trial contributed minimally, if at all, to differences in CV outcomes. We subsequently reported that measurements of visit-to-visit SBP were powerful predictors of CV outcomes, including stroke and coronary eventsand that differences in the effect of the two treatment regimens on systolic BPV explained the benefits of the amlodipine-based treatment observed during the trial. The results obtained by longer term follow-up confirmed our findings at the end of the trial, although the differences in CV outcomes in those formerly assigned the two treatment regimens were less and likely explained by the impact of substantial crossover of treatments during the post-trial period.

In our current analyses, we have restricted our observations to those based on long-term visit-to-visit systolic BPV determined during the ASCOT trial. Our reasoning for this is that we previously reported the outcomes of alternative assessments of BPV in ASCOT, by short-term variability based on 24 h ambulatory BP monitoring and also within visit BPV. We clearly demonstrated that long-term BPV was a far better predictor of CV outcomes than alternative methods of BPV assessmentand, therefore, used this measure in our current study.

Whilst the place of BPV in clinical practice is controversial, there is substantial evidence both from observational studies and clinical trials that long-term visit-to-visit BPV is an important determinant of CV outcomes, as reviewed by Stevens et al. The evidence base is compelling and has persuaded contemporary risk scores to incorporate a measure of visit-to-visit BPV in CV risk assessmentand guidelines to highlight the importance of BPV in patient profiling.

---

### Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients [^2b2b577f]. Nephrology, Dialysis, Transplantation (2008). Low credibility.

Background. Hypertensive haemodialysis patients may be at a high risk for cardiovascular events. This study was undertaken to ascertain whether the calcium channel blocker amlodipine reduces mortality and cardiovascular events in these high-risk patients.

Methods. We evaluated the effects of amlodipine on cardiovascular events in 251 hypertensive haemodialysis patients in an investigator-designed, prospective, randomized, double-blind, placebo-controlled, multicenter trial. One hundred and twenty-three patients were randomly assigned to amlodipine (10 mg once daily) and 128 to placebo. The primary endpoint was mortality from any cause. The secondary endpoint was a composite variable consisting of mortality from any cause or cardiovascular event. Analysis was by intention-to-treat. The trial was registered with ClinicalTrials.gov (number NCT00124969).

Results. The median age of patients was 61 years (25% percentile − 75% percentile, 47–69), and the median follow-up was 19 months (8–30). Fifteen (12%) of the 123 patients assigned to amlodipine and 22 (17%) of the 128 patients assigned to placebo had a primary endpoint [hazard ratio 0.65 (95% CI 0.34–1.23); P = 0.19]. Nineteen (15%) of the 123 haemodialysis patients assigned to amlodipine and 32 (25%) of the 128 haemodialysis patients assigned to placebo reached the secondary composite endpoint [hazard ratio 0.53 (95% CI 0.31–0.93); P = 0.03].

Conclusion. Amlodipine safely reduces systolic blood pressure and it may have a beneficial effect on cardiovascular outcomes in hypertensive haemodialysis patients.

---

### VA / DoD clinical practice guideline for the primary care management of chronic kidney disease [^2519f71d]. DoD/VA (2025). High credibility.

Benazepril/amlodipine versus benazepril/hydrochlorothiazide — Participants were followed for a mean of 36 months, and the primary endpoint was a composite of death from CVD, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization; blood pressure reduction was similar between the two groups. The benazepril/amlodipine combination was superior for reducing CVD events (9.6% vs. 11.8%; p < 0.001), and progression of CKD — defined as doubling of serum creatinine concentration or need for dialysis — was lower with benazepril plus amlodipine (2.0% vs. 3.7%; p < 0.01); heart failure was not included in the CVD composite.

---

### Mortality and morbidity during and after antihypertensive and lipid-lowering treatment to prevent heart attack trial: results by sex [^a85d2338]. Hypertension (2013). Low credibility.

To determine whether an angiotensin-converting enzyme inhibitor (lisinopril) or calcium channel blocker (amlodipine) is superior to a diuretic (chlorthalidone) in reducing cardiovascular disease incidence in sex subgroups, we carried out a prespecified subgroup analysis of 15 638 women and 17 719 men in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Total follow-up (active treatment + passive surveillance using national administrative databases to ascertain deaths and hospitalizations) was 8 to 13 years. The primary outcome was fatal coronary heart disease or nonfatal myocardial infarction. Secondary outcomes included all-cause mortality, stroke, combined cardiovascular disease (coronary heart disease death, nonfatal myocardial infarction, stroke, angina, coronary revascularization, heart failure [HF], or peripheral vascular disease), and end-stage renal disease. In-trial rates of HF, stroke, and combined cardiovascular disease were significantly higher for lisinopril compared with chlorthalidone, and rates of HF were significantly higher for amlodipine compared with chlorthalidone in both men and women. There were no significant treatment sex interactions. These findings did not persist through the extension period with the exception of the HF result for amlodipine versus chlorthalidone, which did not differ significantly by sex. For both women and men, rates were not lower in the amlodipine or lisinopril groups than in the chlorthalidone group for either the primary coronary heart disease outcome or any other cardiovascular disease outcome, and chlorthalidone-based treatment resulted in the lowest risk of HF. Neither lisinopril nor amlodipine is superior to chlorthalidone for initial treatment of hypertension in either women or men. Clinical Trial Registration- clinicaltrials.gov; Identifier: NCT00000542.

---

### Rationale, design, methods and baseline demography of participants of the anglo-scandinavian cardiac outcomes trial. ASCOT investigators [^75d9a2d0]. Journal of Hypertension (2001). Low credibility.

Objective

To test the primary hypothesis that a newer antihypertensive treatment regimen (calcium channel blocker ± an angiotensin converting enzyme inhibitor) is more effective than an older regimen (beta-blocker ± a diuretic) in the primary prevention of coronary heart disease (CHD). To test a second primary hypothesis that a statin compared with placebo will further protect against CHD endpoints in hypertensive subjects with a total cholesterol ≤ 6.5 mmol/l.

Design

Prospective, randomized, open, blinded endpoint trial with a double-blinded 2 × 2 factorial component.

Setting

Patients were recruited mainly from general practices.

Patients

Men and women aged 40–79 were eligible if their blood pressure was ≥ 160 mmHg systolic or ≥ 100 mmHg diastolic (untreated) or ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic (treated) at randomization.

Interventions

Patients received either amlodipine (5/ 10 mg) ± perindopril (4/8 mg) or atenolol (50/ 100 mg) ± bendroflumethiazide (1.25/2.5 mg) +K+ with further therapy as required to reach a blood pressure of ≤ 140 mmHg systolic and 90 mmHg diastolic. Patients with a total cholesterol of ≤ 6.5 mmol/l were further randomized to receive either atorvastatin 10 mg or placebo daily.

Main Outcome Measure

Non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD).

Results

19 342 men and women were initially randomized, of these 10297 were also randomized into the lipid-lowering limb. All patients had three or more additional cardiovascular risk factors.

Conclusions

The study has 80% power (at the 5% level) to detect a relative difference of 20% in CHD endpoints between the calcium channel blocker-based regimen and the beta-blocker-based regimen. The lipid-lowering limb of the study has 90% power at the 1% level to detect a relative difference of 30% in CHD endpoints between groups.

---

### Amlodipine besylate and valsartan (Amlodipine and valsartan) [^4b23b507]. FDA (2018). Low credibility.

Patients with stage 2 hypertension (moderate or severe) are at a relatively higher risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient's risk.

Data from the high-dose multifactorial study [see Clinical Studies (14)] provide estimates of the probability of reaching a blood pressure goal with amlodipine and valsartan tablets compared to amlodipine or valsartan monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with amlodipine and valsartan tablets 10/320 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.

For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 67% likelihood of achieving a goal of < 140 mmHg (systolic) and 80% likelihood of achieving < 90 mmHg (diastolic) on amlodipine alone, and the likelihood of achieving these goals on valsartan alone is about 47% (systolic) or 62% (diastolic). The likelihood of achieving these goals on amlodipine and valsartan tablets rises to about 80% (systolic) or 85% (diastolic). The likelihood of achieving these goals on placebo is about 28% (systolic) or 37% (diastolic).

---

### Diuretic treatment of hypertension [^09d8cc49]. Diabetes Care (2011). Low credibility.

Another major study that failed to demonstrate the superiority of diuretics over comparators was the ANBP2 trial. This was a randomized open-label study between diuretics and ACE inhibitors conducted in 6,083 elderly subjects with hypertension. The ACE inhibitor enalapril and the diuretic hydrochlorothiazide were recommended as initial therapy, but the final choice of the specific agent was left to investigators, who were family practitioners. The primary end point of the study, a composite of CV morbidity and all-cause mortality, was marginally less frequent in the ACE inhibitor group than in the diuretic group (hazard ratio [HR] 0.89, 95% CI 0.79–1.00; P = 0.05).

Diuretics as second-line drugs: outcome-based studies

ASCOT-BPLA (Blood Pressure–Lowering Arm) was a multicenter randomized controlled trial conducted in 19,257 hypertensive patients aged 40–79 years who had at least three other CV risk factors. Patients were randomized to a first-line treatment with either atenolol or amlodipine. In the case of lack of BP control, bendroflumethiazide was added to atenolol and perindopril to amlodipine. Hence, the trial compared an "old-drug" strategy (β-blocker alone or with a diuretic) with a "new-drug" strategy (calcium antagonist alone or with an ACE inhibitor). The trial was stopped prematurely after 5.5 years because of statistically significant lower incidence of all-cause mortality, CV mortality, and other important secondary end points in the new-drug strategy group. The primary end point, a composite of nonfatal myocardial infarction and fatal CHD, did not differ between the groups (HR 0.90, 95% CI 0.79–1.02, P = 0.105).

---

### Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association [^984bceeb]. Circulation (2016). Medium credibility.

Amlodipine — interactions with simvastatin and atorvastatin and safety context are as follows: Coadministration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared with simvastatin alone, whereas coadministration of amlodipine with 80 mg atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin; in the ALLHAT-LLT trial 1122 patients (21.7%) took amlodipine in combination with pravastatin, and no incidence of muscle-related toxicity was reported, and the FDA-approved product labeling for amlodipine indicates that there may be an increased risk of muscle-related toxicity when combined with simvastatin.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^7d64c88e]. Open Heart (2016). Low credibility.

The Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) showed different results on fasting glucose levels. The goal of the FACET was to compare the effects of these two agents on lipid and diabetes control in patients with HTN. Three hundred and eighty patients were randomised to 20 mg of fosinopril or 10 mg of amlodipine daily with a follow-up period of 3.5 years. Results showed no difference on the lipid profiles or fasting glucose levels. However, fosinopril was associated with a 38.5% relative risk reduction (RRR) in the combined end point (fatal or non-fatal stroke and fatal or non-fatal MI; RR = 0.6151, 95% CI 0.3266 to 1.1587). These findings suggest that while amlodipine may have similar effects on BP control, fosinopril may have a greater benefit for the reduction of stroke/MI. However, this trial enrolled a small number of patients and the thus the CIs were wide and the CV event reduction with fosinopril was not significant compared with amlodipine. A larger trial is needed to clarify these results.

Another study by Mugellini and colleagues looked at 391 patients with metabolic syndrome who had at least two episodes of atrial fibrillation (AF) in 6 months. These patients were randomised to telmisartan, ramipril or amlodipine for 12 months and results showed that all three groups similarly reduced both systolic and diastolic BP. In terms of the AF however, telmisartan showed the greatest effect on reducing recurrence.

---

### Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT [^989cc96c]. The American Journal of Medicine (2017). Low credibility.

Background

Although hypertension guidelines define treatment-resistant hypertension as blood pressure uncontrolled by ≥ 3 antihypertensive medications, including a diuretic, it is unknown whether patient prognosis differs when a diuretic is included.

Methods

Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) were randomly assigned to first-step therapy with chlorthalidone, amlodipine, or lisinopril. At a Year 2 follow-up visit, those with average blood pressure ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic on ≥ 3 antihypertensive medications, or blood pressure < 140/90 mm Hg on ≥ 4 antihypertensive medications were identified as having apparent treatment-resistant hypertension. The prevalence of treatment-resistant hypertension and its association with ALLHAT primary (combined fatal coronary heart disease or nonfatal myocardial infarction) and secondary (all-cause mortality, stroke, heart failure, combined coronary heart disease, and combined cardiovascular disease) outcomes were identified for each treatment group.

Results

Of participants assigned to chlorthalidone, amlodipine, or lisinopril, 9.6%, 11.4%, and 19.7%, respectively, had treatment-resistant hypertension. During mean follow-up of 2.9 years, primary outcome incidence was similar for those assigned to chlorthalidone compared with amlodipine or lisinopril (amlodipine- vs chlorthalidone-adjusted hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.53–1.39; P = 0.53; lisinopril- vs chlorthalidone-adjusted HR = 1.06; 95% CI, 0.70–1.60; P = 0.78). Secondary outcome risks were similar for most comparisons except coronary revascularization, which was higher with amlodipine than with chlorthalidone (HR 1.86; 95% CI, 1.11–3.11; P = 0.02). An as-treated analysis based on diuretic use produced similar results.

Conclusions

In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension. However, prognoses in those with treatment-resistant hypertension were similar across treatment groups.

---

### Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes [^1dd5a8cc]. Open Heart (2016). Low credibility.

Role in HF

Traditionally CCBs were discontinued for the treatment of angina or HTN in patients with HF. Previous studies with CCBs such as nifedipine, have shown unfavourable effects due to reflex stimulation of the sympathetic nervous system and negative inotropic effects, features not seen with amlodipine. Thus, amlodipine may be safe in patients with HF. The Prospective Randomized Amlodipine Survival Evaluation (PRAISE) trial established the safety of amlodipine for angina and HTN in patients with advanced LV dysfunction (amlodipine). The PRAISE trial studied over 1100 patients with severe ischaemic and non-ischaemic New York Heart Association class III and IV HF with an LV ejection fraction (LVEF) of < 30% despite being on digoxin, diuretics or an ACEI. They were also allowed to be on a nitrate but no other vasodilating therapy. They were randomised to either amlodipine or placebo and followed for 33 months. There was no significant difference in the primary end point (combined risk of all-cause mortality and CV disease morbidity) with amlodipine treatment; although amlodipine did show a 9% risk reduction of a primary fatal or non-fatal event. There was a difference however, in the non-ischaemic HF group, where amlodipine showed a 46% reduction in mortality.

The PRAISE trial showed that amlodipine did not affect the natural history of HF or increase the risk of death as other trials with CCBs have suggested. The investigators pointed out that it was interesting that amlodipine seemed to greatly benefit the non-ischaemic group. The PRAISE II trial was then carried out to further investigate the potential for amlodipine to reduce mortality in the non-ischaemic group. This trial looked at 1652 patients with normal arteriograms but with the systolic HF and average LVEF was 21%. There was no significant difference found between the amlodipine versus placebo group in terms of all-cause or CV disease mortality or CV disease events. Taken together, PRAISE I and II suggest that amlodipine can be safely used to treat angina or HTN in patients with coexisting HF.

---

### Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients [^289e1ceb]. Journal of the American Heart Association (2018). Low credibility.

Strengths and Limitations

We are aware of only 1 prior analysis from a major hypertension trial (VALUE [Valsartan Antihypertensive Long‐Term Use Evaluation]) in which the impact on study outcomes was evaluated in relation to prior BP‐lowering treatment regimens. 15 As with the ACCOMPLISH trial, most study patients (92%) had been receiving antihypertensive therapy before entering the VALUE trial. In accordance with our findings, the study end points were not differentially affected by prior medications. This is a particularly relevant issue for contemporary clinical practice because most patients among modern trials had been already undergoing treatment with medications. 1

We acknowledge that our results derive from post hoc observational analyses and, as such, must be considered hypothesis generating. Nevertheless, the consistency of responses favoring benazepril+amlodipine among all subgroups supports the overall veracity of our overarching contention. In addition, our findings only directly apply to high‐risk individuals given the characteristics of the patients in ACCOMPLISH. 6 Whether the results can be extrapolated to other and lower‐risk patients is unknown; however, recent evidence supports that medical treatment is likely beneficial, even for low‐risk patients with mild hypertension. 1 Positive findings in our study were observed in patients previously taking several single BP‐lowering medications and those with a systolic/diastolic BP of < 140/90 mm Hg, supporting the hypothesis that even individuals with milder forms of high BP may benefit from benazepril+amlodipine. The average on‐treatment BP in the ACCOMPLISH trial was < 140/90 mm Hg. Thus, any speculations of the merits of initiating combination therapy with benazepril+amlodipine implicitly presume that this regimen is capable of keeping BP controlled (alone or with additional agents as needed). This is particularly important given the recent results of the SPRINT (Systolic Blood Pressure Intervention Trial), which also supports a lower systolic BP target (120 mm Hg) than previously espoused. 16 Patients were allocated to a subgroup on the basis of the medications they were taking right at study enrollment. The duration they had been treated with these agents, prior medication use in the years beforehand, and their adherence to this regimen remain unknown. However, because most subgroups derived similar relative benefits from benazepril+amlodipine, it is not likely that any unaccounted for changing of prior medications between the various regimens in the months to years before entering the trial would have differentially affected the treatment effects of the combination therapy regimens used in the ACCOMPLISH trial in a manner that explains our current findings. Finally, we were not able to explain the significantly greater benefit of benazepril+amlodipine in the ACEI+CCB subgroup (Table 3). It remains possible that unaccounted for factors (ie, not listed in Table 4) could have led to a propensity to receive ACEI+CCB combination and, thus, explains the greater benefit in this 1 subgroup.

---

### Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial [^90234de9]. Circulation (2006). Low credibility.

Background

Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF.

Methods and Results

ALLHAT was a double-blind, randomized, clinical trial in 33,357 high-risk hypertensive patients aged ≥ 55 years. Hospitalized/fatal HF outcomes were examined with proportional-hazards models. Relative risks (95% confidence intervals; P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50; < 0.001) and 1.11 (0.99 to 1.24; 0.09). The proportional hazards assumption of constant relative risk over time was not valid. A more appropriate model showed relative risks of amlodipine or lisinopril versus chlorthalidone during year 1 were 2.22 (1.69 to 2.91; < 0.001) and 2.08 (1.58 to 2.74; < 0.001), and after year 1, 1.22 (1.08 to 1.38; P = 0.001) and 0.96 (0.85 to 1.10; 0.58). There was no significant interaction between prior medication use and treatment. Baseline blood pressures were equivalent (146/84 mm Hg) and at year 1 were 137/79, 139/79, and 140/80 mm Hg in those given chlorthalidone, amlodipine, and lisinopril. At 1 year, use of added open-label atenolol, diuretics, angiotensin-converting enzyme inhibitors, and calcium channel blockers in the treatment groups was similar.

Conclusions

HF risk decreased with chlorthalidone versus amlodipine or lisinopril use during year 1. Subsequently, risk for those individuals taking chlorthalidone versus amlodipine remained decreased but less so, whereas it was equivalent to those given lisinopril. Prior medication use, follow-up blood pressures, and concomitant medications are unlikely to explain most of the HF differences. Diuretics are superior to calcium channel blockers and, at least in the short term, angiotensin-converting enzyme inhibitors in preventing HF in hypertensive individuals.

---

### Amlodipine (Norliqva) [^05c29183]. FDA (2022). Medium credibility.

In an angiographic substudy (n = 274) conducted within CAMELOT, there was no significant difference between amlodipine and placebo on the change of atheroma volume in the coronary artery as assessed by intravascular ultrasound.

Figure 1 - Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo

Figure 2 – Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups

Table 1 below summarizes the significant composite endpoint and clinical outcomes from the composites of the primary endpoint. The other components of the primary endpoint including cardiovascular death, resuscitated cardiac arrest, myocardial infarction, hospitalization for heart failure, stroke/TIA, or peripheral vascular disease did not demonstrate a significant difference between amlodipine and placebo.

Table 1 – Incidence of Significant Clinical Outcomes for CAMELOT

* Total patients with these events

---

### The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study [^79ffa42f]. Clinical Therapeutics (2008). Low credibility.

Background

Hypertension guidelines recommend the use of 2 agents having complementary mechanisms of action when > 1 agent is needed to achieve blood pressure (BP) goals.

Objective

The aim of this study was to compare the efficacy and tolerability of combinations of olmesartan medoxomil (OM) and amlodipine besylate with those of the component monotherapies in patients with mild to severe hypertension.

Methods

This was a multicenter, randomized, double-blind, placebo-controlled, factorial study. Patients who were naive to antihypertensive therapy or who underwent a washout of previous antihypertensive therapy for up to 2 weeks and had a seated diastolic BP (SeDBP) of 95 to 120 mm Hg were randomized to receive 1 of the following for 8 weeks: OM 10, 20, or 40 mg; amlodipine (AML) 5 or 10 mg; each possible combination of OM and AML; or placebo. The primary end point was the change from baseline in SeDBP at week 8, with secondary end points including the change in seated systolic blood pressure (SeSBP), the proportion of patients reaching the BP goal (< 140/90 mm Hg; < 130/80 mm Hg for patients with diabetes), and the proportions of the intention-to-treat population reaching BP thresholds of < 120/80, < 130/80, < 130/85, and < 140/90 mm Hg. Safety and tolerability were also evaluated, with a particular focus on the incidence and severity of edema.

Results

Of the 1940 randomized patients, 54.3% were male. The mean age of the study population was 54.0 years and 19.8% were aged ≥ 65 years. The mean baseline BP was 164/102 mm Hg, and 79.3% of patients had stage 2 hypertension. Combination therapy with OM and AML was associated with dose-dependent reductions in SeDBP (from -13.8 mm Hg with OM/AML 10/5 mg to -19.0 mm Hg with OM/AML 40/10 mg) and SeSBP (from -23.6 mm Hg with OM/AML 20/5 mg to -30.1 mm Hg with OM/AML 40/10 mg) that were significantly greater than the reductions with the corresponding component monotherapies (P < 0.001). At week 8, the number of patients achieving the BP goal ranged from 57 of 163 (35.0%) to 84 of 158 (53.2%) in the combination-therapy groups, from 32 of 160 (20.0%) to 58 of 160 (36.3%) in the OM monotherapy groups, and from 34 of 161 (21.1%) to 53 of 163 (32.5%) in the AML monotherapy groups (P < 0.005, combination therapies vs component monotherapies), compared with 14 of 160 (8.8%) in the placebo group. Achievement of the BP thresholds was highest in the combination-therapy groups, with 56.3% and 54.0% of patients achieving a BP < 140/90 mm Hg with OM/AML 20/10 and 40/10 mg, respectively. Combination therapy was generally well tolerated, and no unexpected safety concerns emerged in the course of the study. The most common adverse events were edema (ranging from 9.9% [OM 20 mg] to 36.8% [AML 10 mg], compared with 12.3% with placebo) and headache (ranging from 2.5% [OM/AML 10/5 mg] to 8.7% [OM 20 mg], compared with 14.2% with placebo).

Conclusion

The combination of OM and AML was effective and well tolerated in this adult population with hypertension.

---

### The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy [^31d9ddd8]. Hypertension (2006). Low credibility.

In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N = 3263) and amlodipine (N = 3817) groups. Time on monotherapy was 3.2 years (78% of treatment exposure time). The average in-trial blood pressure was similar in both groups. Event rates in the monotherapy group were 16% to 39% lower than in the main VALUE trial. In the first analysis, we censored patients when they discontinued monotherapy ("censored"); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle). We also assessed the impact of duration of monotherapy on outcomes. No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses. Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 0.63, P = 0.004 and 0.78, P = 0.045, respectively). Longer duration of monotherapy amplified between-group differences in heart failure. New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 0.78, P = 0.012 and 0.82, P = 0.034). Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan. Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients.

---

### Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial [^bd351bf1]. Journal of Hypertension (2006). Low credibility.

Context

Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease.

Objective

To test for the first time the hypothesis that treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker (ARB) valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine.

Design

Pre-specified analysis in the VALUE trial. Follow-up averaged 4.2 years. The risk of developing new diabetes was calculated as an odds ratio (OR) with 95% confidence intervals (CI) for different definitions of diabetes.

Patients

A sample of 9995 high-risk, non-diabetic hypertensive patients.

Interventions

Valsartan or amlodipine with or without add-on medication [hydrochlorothiazide (HCTZ) and other add-ons, excluding other ARBs, angiotensin-converting enzyme (ACE) inhibitors, CCAs].

Main Outcome Measure

New diabetes defined as an adverse event, new blood-glucose-lowering drugs and/or fasting glucose > 7.0 mmol/l.

Results

New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (OR 0.77, 95% CI 0.69–0.87, P < 0.0001). Using stricter criteria (without adverse event reports) new diabetes was detected in 495 (9.8%) patients on valsartan and in 586 (11.8%) on amlodipine (OR 0.82, 95% CI 0.72–0.93, P = 0.0015).

Conclusion

Compared with amlodipine, valsartan reduces the risk of developing diabetes mellitus in high-risk hypertensive patients.

---

### 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association / American stroke association [^5c407639]. Stroke (2024). High credibility.

First-step antihypertensive medication selection — comparative effectiveness and guideline position: A meta-analysis of first-step treatments found diuretic, β-blocker, calcium channel blocker, angiotensin-converting enzyme inhibitor, and angiotensin receptor blocker agents were more effective than placebo for prevention of stroke; subsequent meta-analyses showed first-step therapy with β-blockers was inferior to the other classes and that calcium channel blocker treatment was the most consistently beneficial. In the most scientifically rigorous RCT comparison, there was no superiority for prevention of stroke in those randomized to amlodipine or lisinopril compared with the thiazide-type diuretic chlorthalidone, although chlorthalidone was superior for prevention of heart failure. The ACC/AHA BP guideline recommends the use of diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers for first-step antihypertensive drug therapy.

---

### Amlodipine and atorvastatin [^39e482bc]. FDA (2025). Medium credibility.

14.6	Atorvastatin for Prevention of Cardiovascular Disease

In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of atorvastatin on fatal and non-fatal coronary heart disease was assessed in 10,305 patients with hypertension, 40 years to 80 years of age (mean of 63 years; 19% women; 95% White, 3% Black, 1% South Asian, 1% other), without a previous myocardial infarction and with total-cholesterol (TC) levels ≤ 251 mg/dL. Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81%), age > 55 years (85%), smoking (33%), diabetes (24%), history of CHD in a first-degree relative (26%), TC:HDL > 6 (14%), peripheral vascular disease (5%), left ventricular hypertrophy (14%), prior cerebrovascular event (10%), specific ECG abnormality (14%), proteinuria/albuminuria (62%). In this double-blind, placebo-controlled trial, patients were treated with antihypertensive therapy (goal BP < 140/90 mm Hg for patients without diabetes; < 130/80 mm Hg for patients with diabetes) and allocated to either atorvastatin 10 mg daily (n = 5168) or placebo (n = 5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.

---

### Lercanidipine in the treatment of hypertension [^ab3830a2]. The Annals of Pharmacotherapy (2007). Low credibility.

Objective

To review the literature regarding the efficacy, tolerability, and utility of lercanidipine in the treatment of hypertension.

Data Sources

A search of the literature was performed using MEDLINE (1966-September 2006), EMBASE Drugs and Pharmacology (1980-September 2006), and Current Contents/Clinical Medicine (week 24, 2005-week 30, 2006). Package inserts from lercanidipine, nifedipine, felodipine, and amlodipine were also reviewed for comparison of adverse effects.

Study Selection and Data Extraction

Articles were limited to clinical trials, abstracts, and review articles published in English.

Data Synthesis

Lercanidipine is a novel dihydropyridine (DHP) calcium-channel blocker indicated for the treatment of mild-to-moderate hypertension. Although it is not yet available in the US, lercanidipine has been utilized extensively in other countries. In 2 randomized controlled trials of approximately 400 patients with mild-to-moderate hypertension, lercanidipine showed efficacy similar to that of 2 other DHPs, felodipine and slow-release nifedipine, in significantly reducing systolic blood pressure and diastolic blood pressure (DBP) after 4 weeks. In a longer trial (12 mo), lercanidipine 10 mg/day led to normalized blood pressure in 49% of patients after 4 weeks. A postmarketing trial of 9050 patients corroborated the results observed in previous clinical trials, with 64% of patients achieving a DBP of less than 90 mm Hg and 32% attaining blood pressure control (< 140/90 mm Hg). In elderly patients, lercanidipine was found comparable with lacidipine and nifedipine, showing similar decreases in DBP when compared with nifedipine (-18.3 vs -17.7 mm Hg, respectively). What distinguishes lercanidipine from other members of the DHP class is its lower incidence of adverse effects, particularly edema. One study showed that fewer patients withdrew secondary to adverse drug reactions in the lercanidipine (0.9%) and nifedipine (3.8%) group compared with the felodipine (4.5%) group. Lercanidipine has also shown efficacy similar to that of other antihypertensives, including atenolol, captopril, and losartan.

Conclusions

Lercanidipine may be an option in the treatment of hypertension, as current literature suggests comparable antihypertensive efficacy and better tolerability. Further randomized, double-blind clinical trials must be conducted in order to clarify its position among other antihypertensive medications.

---

### Amlodipine besylate and atorvastatin calcium [^424f2bf6]. FDA (2021). Medium credibility.

1 INDICATIONS AND USAGE

Amlodipine besylate and atorvastatin calcium tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.

Amlodipine

1.1 Hypertension

Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Amlodipine may be used alone or in combination with other antihypertensive agents.